

**A CROSS SECTIONAL STUDY ON THE PREVALENCE
OF COMORBIDITIES AMONG THE SARS-COV-2 DEATHS REPORTED IN
TERTIARY CARE CENTRE**

**A Dissertation Submitted to
THE TAMILNADU DR. M.G.R MEDICAL UNIVERSITY
CHENNAI**

In Partial Fulfilment of the Regulations

For the Award of the Degree of

M.D. (GENERAL MEDICINE) - BRANCH – I

Register Number 200120102508



THANJAVUR MEDICAL COLLEGE

Thanjavur - 04

THE TAMILNADU DR.MGR MEDICAL UNIVERSITY, CHENNAI

MAY -2023

CERTIFICATE FROM THE GUIDE

This is to certify that this dissertation entitled " **A CROSS SECTIONAL STUDY ON THE PREVALENCE OF COMORBIDITIES AMONG THE SARS-COV 2 DEATHS REPORTED IN TERTIARY CARE CENTRE** " submitted by **DR.M.NIVEDHAN** to The TamilNadu Dr.M.G.R. Medical University, Chennai is in partial fulfillment of the requirement for the award of **M.D.GENERAL MEDICINE** and is a bonafide research work carried out by him under my direct supervision and guidance. All the observations and conclusions have been made by the candidate himself and have been checked by me periodically. This work has not previously formed the basis for the award of any degree or diploma.

Place : Thanjavur.
Date : 08.12.2022



Prof Dr.C.PARANTHAKAN, M.D.,
Head Of The Department,
Department Of General Medicine,
Thanjavur Medical College Thanjavur.

Dr.C.PARANTHAKAN, M.D.,
Reg. No: 43149
HOD & Professor
Department of Medicine
Thanjavur Medical College & Hospital,
Thanjavur - 613 004.


CERTIFICATE

This is to certify that the dissertation entitled "A CROSS SECTIONAL STUDY ON THE PREVALENCE OF COMORBIDITIES AMONG THE SARS-COV 2 DEATHS REPORTED IN TERTIARY CARE CENTRE" is a bonafide original work of Dr.M.NIVEDHAN., in partial fulfillment of the requirements for M.D. Branch- I (General Medicine) Examination of The Tamil Nadu Dr. M.G.R Medical University to be held in MAY 2023 under my guidance and supervision during the period of June 2020- June 2021. This work has not previously formed the basis for the award of any degree or diploma.



Dr.C.PARANTHAKAN, MD.,
Guide for the Study
Professor and HOD,
Department of General Medicine,
Thanjavur Medical College and Hospital,
Thanjavur.


Dr.C.PARANTHAKAN, MD.,
Reg. No: 43149
HOD & Professor
Department of Medicine
Thanjavur Medical College & Hospital,
Thanjavur - 613 004.



Dr.R.BALAJINATHAN, MD.,
Dean,
Thanjavur Medical College and Hospital
Thanjavur.

DEAN,
Thanjavur Medical College,
Thanjavur.

INSTITUTIONAL ETHICAL COMMITTEE CLEARANCE



**THANJAVUR MEDICAL COLLEGE
INSTITUTIONAL ETHICAL
COMMITTEE FOR HUMAN STUDIES**



Registered under National Ethics Committee Registry for Biomedical and Health Research
(NECBHR), Ministry of Health and Family Welfare, Govt of India
(Reg. No: EC/NEW/INST/2020/1058)

CERTIFICATE

No: 891/2021

TITLE OF THE STUDY:
A cross sectional study on the prevalence of comorbidities among the SARS-Cov-2 deaths reported in Thanjavur Medical College.

PRINCIPAL INVESTIGATOR:
Dr. M. Nivedhan, Postgraduate in Department of General Medicine, Thanjavur Medical College.

This to certify that the protocol submitted by the principal investigator of the above mentioned study has been reviewed as per standard ethical guidelines and the same has been **APPROVED** by the members of the Institutional ethical committee at its meeting held on 21.01.2021.



Dr. N. Anumugem M.D.,
Member Secretary of IEC
Vice Principal & Professor of Pathology,
Thanjavur Medical College
Thanjavur

Chairman:
Dr. J. Venkatesan M.D.,
MR Pathologist of Psychiatry,
SRM South Kamal Hospital,
Thanjavur.

Member Secretary:
Dr. N. Anumugem M.D.,
Professor of Pathology,
Thanjavur Medical College.

Members:

Dr. S. Kumaravel M.Ch, MR, MRG
Professor of Otolaryngology, TMC.

Dr. Rajamony Ramani M.D.,
Professor of Dermatology, TMC.

Dr. Lakshmi Anand M.S.,
Assistant Professor of O.G & Gynae,
TMC.

Dr. S. Sreerajal S.D.C, M.B.
Assistant Professor of
Paediatrics, TMC.

Dr. M. Anandharaj M.D.,
Associate Professor of
Pathology, TMC.

Dr. Kavita Srinivas Jaiswal M.D.
Associate Professor of
Histopathology, TMC.

Dr. A. Vinith M.D.
Assistant Professor of Internal
Medicine, TMC.

Dr. S. Sathyanarayanan M.A.,
Assistant Professor of General
Surgery, TMC.

Dr. L. Rajagopalan M.D.,
Assistant Professor of
Yeastology, TMC.

Dr. S. Srinivasan M.A., MCh,
Assistant Professor,
Dept. of General Surgery,
Tamil Government Hospital,
Thanjavur.

Dr. A. Rajasekaran S.K., B.L.,
Ayurveda Specialist,
Thanjavur.

Dr. S. Prasad
Senior Lecturer, Government
College, Thanjavur.

ANTI - PLAGIARISM CERTIFICATE



Document Information

Analyzed document	STUDY OF PREVALENCE OF COMORBIDITIES AMONG SARS-COV2 DEATHS.docx (D150666306)
Submitted	11/25/2022 10:25:00 AM
Submitted by	M.NIVEDHAN
Submitter email	ninjanivee@gmail.com
Similarity	8%
Analysis address	ninjanivee.tnmg@analysis.urkund.com

Sources included in the report

Entire Document

Hit and source - focused comparison, Side by Side

Submitted text	As student entered the text in the submitted document.
Matching text	As the text appears in the source.

CERTIFICATE FOR PLAGIARISM

This is to certify that this dissertation work entitled " **A CROSS SECTIONAL STUDY ON THE PREVALENCE OF COMORBIDITIES AMONG THE SARS-COV 2 DEATHS REPORTED IN TERTIARY CARE CENTRE** "is a bonafide record of work done by the candidate **Dr. M.NIVEDHAN** , with Registration number **200120102508** for the award of Master's degree in the branch of **GENERAL MEDICINE** . I have personally verified the urkund.com website (Original) for plagiarism check. I found that the uploaded thesis file contains from introduction to limitation pages and results shows of **8 %** plagiarism in the dissertation.



Prof Dr.C.Paranthakan, M.D.,
Head Of The Department,
Department Of General Medicine,
Thanjavur Medical College and
Hospital, Thanjavur

Dr, C. PARANTHAKAN, M.D.,
Reg. No: 43149
HOD & Professor
Department of Medicine
Thanjavur Medical College & Hospital.
Thanjavur - 613 004.

DECLARATION BY THE CANDIDATE

I, **Dr.M.NIVEDHAN** solemnly declare that the dissertation titled “ **A CROSS SECTIONAL STUDY ON THE PREVALENCE OF COMORBIDITIES AMONG THE SARS-COV 2 DEATHS REPORTED IN TERTIARY CARE CENTRE** ” is a bonafide work done by me at Thanjavur Medical College , Thanjavur during 2020 JUNE TO 2021 JUNE under the guidance and supervision of **Prof Dr.C.Paranthakan M.D.**, Unit Chief M1 And Head Of The Department , Department Of Internal Medicine , Thanjavur Medical College , Thanjavur . I also declare that this bonafide work or a part of this work was not submitted by me or any other for any award, degree and diploma to any university, board either in India or abroad.This dissertation is submitted to Dr. M.G.R Medical University, TamilNadu towards the partial fulfillment of requirement for the award of **M.D. Degree (Branch -I) in General Medicine.**

Place : Thanjavur.

Date : 08.12.2022



Dr.M.Nivedhan,
Post graduate in General Medicine,
Thanjavur Medical College.

ACKNOWLEDGEMENTS

The task of acknowledging my sense of gratitude and indebtedness to all those who are involved in completion of this study, is not possible in words within few limits.

First and foremost, I would like to praise the Almighty, the Most Gracious, and the Most Merciful for His blessing given to me during my study and in completing this thesis.

I would like to thank **Prof.Dr.R.Balajinathan,MD.**, Dean,Thanjavur Medical College, for permitting me to conduct and utilize the clinical materials of the hospital for the successful execution of this dissertation.

I express my deep and heartiest sense of immense gratitude to my esteemed mentor and guide **Prof.C.Paranthakan, MD.**, Professor and Head of the Department of General Medicine , Thanjavur Medical College under whose direct supervision and guidance, this study was done. His invaluable guidance, constant supervision, expert criticism and sustained encouragement has made this work possible.

I take my opportunity of expressing my profound sense of gratitude to **Dr.A.Magesh,MD.**,Senior Assistant Professor, Department of General Medicine , Thanjavur Medical College & Hospital, Thanjavur for his constant encouragement and valuable guidance made me complete this work.

I am specially grateful to **Dr.K.Rajkanth, MD.**, Assistant Professor, Department of General Medicine,Thanjavur Medical College & Hospital, Thanjavur for his constant encouragement and invaluable suggestion.

I acknowledge my gratitude to all my Post Graduate colleagues for their emotional support and cooperation.I also sincerely thank other staff members of General Medicine department for their co-operation throughout the period of this study.

I also extend my deep sense of gratitude to my mother and my father who with their affection, encouragement and support, have been a source of strength to me.

Finally, I thank all the patients, who form the most vital part of my work, without whom this project would have been a distant dream.

LIST OF FIGURES

Figure 1 Life cycle of corona virus	9
Figure 2. Inflammatory mechanism, damage of the alveolar epithelium and endothelium, and coagulopathy in COVID-19.....	10
Figure 3 Clinical spectrum of covid.....	10
Figure 4. Pathophysiology and clinical features of COVID-19	12
Figure 5 Effects of covid 19 on diabetes	16
Figure 6 Covid 19 and hypertension.....	19
Figure 7 Cardiovascular disease and Covid 19	21
Figure 8 Covid 19 and malignancy	22
Figure 9 Age distribution among the population	34
Figure 10 Frequency distribution of age category of deceased Covid-19 patients observed in the study.	35
Figure 11 Frequency distribution of gender category of deceased Covid-19 patients observed in the study.	36
Figure 12 Frequency distribution of locality of deceased Covid-19 patients observed in the study	38
Figure 13 Frequency distribution of occurrence of comorbidity observed in the deceased Covid-19 patients	39
Figure 14 Frequency distribution of type of comorbidity observed in the deceased Covid-19 patients.	41
Figure 15 Frequency description of number of days of symptoms before Covid-19 admission observed in the study	44
Figure 16 Frequency description of number of comorbidity category observed in the deceased Covid-19 patients.....	45

Figure 17 Frequency description of duration of comorbidity category observed in the deceased Covid-19 patients	46
Figure 18 Comparison of age with respect to gender category in deceased Covid-19 patients	49
Figure 19 Comparison of comorbidity status with respect to gender in deceased Covid-19 patients	50

LIST OF TABLES

Table 1. Clinical spectrum of the Covid-19	11
Table 2 Age distribution among the population.....	34
Table 3. Frequency distribution of age category of deceased Covid-19 patients observed in the study.	35
Table 4. Frequency distribution of gender category of deceased Covid-19 patients observed in the study.....	36
Table 5 Frequency distribution of locality of deceased Covid-19 patients observed in the study.....	37
Table 6 Frequency distribution of occurrence of comorbidity observed in the deceased Covid-19 patients.....	39
Table 7 Frequency distribution of type of comorbidity observed in the deceased Covid- 19 patients.....	40
Table 8 Description of other comorbidity conditions observed in deceased Covid-19 patients. 	42
Table 9 Frequency description of number of days of symptoms before Covid-19 admission observed in the study.....	43
Table 10 Frequency description of number of comorbidity category observed in the deceased Covid-19 patients	45
Table 11 Frequency description of duration of comorbidity category observed in the deceased Covid-19 patients	46
Table 12 The distribution of hospital stay in hours duration	47
Table 13. Comparison of age with respect to gender category in deceased Covid-19 patients.....	48

Table 14 Comparison of comorbidity status with respect to gender in deceased Covid-19 patients	49
Table 15 Comparison of comorbidity status with respect to age in deceased Covid-19 patients	50
Table 16. Comparison of Comorbid status with respect to age category in deceased Covid-19 patients.....	51
Table 17 Correlation of ‘time spent in hospital’ before death with respect to various factors in deceased Covid-19 patients.....	52
Table 18 Comparison of duration of ‘time spent in hospital before death’ (in hours) between the patients with comorbidity status in deceased Covid-19 patients.....	53
Table 19 Comorbid prevalence among deceased covid 19 subjects in different studies.....	56

TABLE OF CONTENTS

1	ABSTRACT	1
2	INTRODUCTION.....	3
3	AIM AND OBJECTIVES.....	6
3.1	AIM.....	6
3.2	OBJECTIVES.....	6
4	REVIEW OF LITERATURE.....	7
4.1	Covid 19- clinical features and pathogenesis.....	8
4.2	Comorbidities and covid 19	14
4.3	Studies Related To The Topic	23
5	RESEARCH QUESTION OR HYPOTHESIS.....	27
5.1	Research Question	27
5.2	Null Hypothesis	27
5.3	Alternate Hypothesis.....	27
6	METHODOLOGY.....	28
6.1	Study Subjects	28
6.2	Study Design	28
6.3	Study setting.....	28
6.4	Sampling Procedure.....	28
6.5	Inclusion Criteria	28

6.6	Exclusion criteria	28
6.7	Sample Size	29
6.8	Study procedure	30
6.9	Ethical Consideration	30
6.10	Study Period	30
6.11	Statistical Methods	31
7	RESULTS	33
	Descriptive Statistics	33
	Inferential Statistics	33
8	DISCUSSION	54
9	LIMITATIONS	59
10	RECOMMENDATIONS	60
11	CONCLUSION	61
12	SUMMARY OF RESULTS	62
13	REFERENCES	65
14	ANNEXURES	85

LIST OF ABBREVIATIONS

ACE-2 – Angiotensin Converting Enzyme - 2

ARB – Angiotensin Receptor Blocker

ARDS- Acute Respiratory Distress Syndrome

AT2 – Angiotensin -2

AWMI- Anterior Wall Myocardial Infarction

BPH – Benign Prostatic Hyperplasia

CABG- Coronary Artery Bypass Graft

CAD- Coronary Artery Disease

CKD – Chronic Kidney Disease

COPD – Chronic Obstructive Pulmonary Disease

COVID-19 – Corona Virus Disease - 19

CVA – Cerebrovascular Accident

DCLD – Decompensated Chronic Liver Disease

DIC – Disseminated Intravascular Coagulation

DKA- Diabetic Keto Acidosis

DM- Diabetes Mellitus

DPP4 – Dipeptidyl Peptidase -4

DVT- Deep Venous Thrombosis

G-CSF – Granulocyte – Colony Stimulating Factor

GERD – Gastroesophageal Reflux Disease

GM-CSF- Granulocyte Monocyte – Colony Stimulating Factor

HCV- Hepatitis C Virus

HIV – Human Immunodeficiency Virus

ICU – Intensive Care Unit

IFN- γ – Interferon Gamma

IGG – Immunoglobulin G

IL-1 – Interleukin - 1

IL-6 – Interleukin-6

IL-8- Interleukin-8

IL-10 – Interleukin-10

LVH – Left Ventricular Hypertrophy

MCP-1 – Monocyte Chemoattractant Protein - 1

MIP-2- Macrophage Inflammatory Protein -2

MR- Mitral Regurgitation

NADPHO- Nicotinamide Adenine Dinucleotide Phosphate Oxidase

NO- Nitric Oxide

NSTEMI – Non ST Elevation Myocardial Infarction

PCR- Polymerase Chain Reaction

PTB – Pulmonary Tuberculosis

RAAS – Renin Angiotensin Aldosterone System

ROS – Reactive Oxygen Species

RT-PCR- Reverse Transcriptase – Polymerase Chain Reaction

RTA – Road Traffic Accident

SARI – Severe Acute Respiratory Illness

SARS-COV-2 – Severe Acute Respiratory Syndrome Coronavirus 2

SHT – Systemic Hypertension

SLE – Systemic Lupus Erythematosus

STEMI – ST Segment Elevated Myocardial Infarction

TMPRSS2- Transmembrane Proteinase Serine 2

1 ABSTRACT

Introduction:

The strength and power of a disease is always determined by its case fatality rate . The new SARS-COV-2 pandemic have been made significant panic with its mortality among subjects with underlying health conditions and age extremes.

Objectives:

The study was done with an objective to assess the impact of Covid-19 infection on the most frequent comorbidities encountered amongst those who have died due to this pathogen. The study also wanted to identify the high-risk group in this pandemic and prioritising them for vaccination. And also, to estimate the most prevalent comorbidity in the study population.

Methodology:

The study was done as a retrospective observational study among subjects who deceased due to Covid-19 in a particular period. The study was done among 796 deceased subjects who were selected consecutively from deaths reported due to Covid-19 between June 2020 and June 2021 as reported by the Ministry of Health. Deaths with confirmed RT-PCR positive result for SARS-COV-2 and patients with age >15 years were included in the study. Patients who recovered from SARS-COV-2 infection and reactive patients who were discharged and later expired due to other causes were excluded from the study. The available data generally included information about the age, gender, confirmed positive, the date of

death and their underlying comorbidities. The data was entered into Microsoft excel and analysed using SPSS 23.

Results:

The mean (SD) of age in years among the population was 60.35(13.41) years. In the study 554(69.6%) subjects who deceased due to Covid-19 were males and 242(30.4%) were females. Among the deceased Covid-19 patients showed that 616(77.4%) subjects had presence of co-morbidities. The Frequency distribution of type of comorbidity observed in the deceased Covid-19 patients showed that Diabetes mellitus (DM) was present for 431(70%), Systemic hypertension (SHT) 334(54.2%), Coronary artery disease(CAD) 124(20.1%) and Chronic kidney disease(CKD)93(15.1%).In the study subjects presence of comorbidity was significantly older than those without comorbidity[61.58(11.93) vs. 56.15(16.91)]The comorbid status with respect to age shows that majority of comorbidity were present in the age group of 61-80 years 303(49.2%) and 41-60 years (259(42%). The correlation between time spent in hospital before death with age, number of days of symptoms before admission, duration and number of comorbidities and comorbidity status were not significantly different.

Conclusion:

The study showed that male gender, older subjects were mostly deceased among the population. The study showed diabetes and hypertension to be the most prevalent comorbidities and no significant difference in duration of hospital stay with the presence of comorbidities.

Keywords:

Covid-19, SARS COV-2, Comorbidities, Prevalence

2 INTRODUCTION

Currently, world is witnessing a pandemic with the emergence of SARS-CoV-2 virus, greater than the 1918–19 Spanish influenza pandemic in terms of the morbidity, mortality and economic disruptions.¹ First cases of Covid-19 were reported in Wuhan, China, in December 2019. As of April 25, 2021, 220 countries are affected and countries such as USA, Brazil, Mexico, and India (equalling >1.3million deaths and >65million infections) were most affected.^{2,3}

India's first Corona virus infection was confirmed in Kerala on January 27, 2020.⁴ Tamilnadu reported it's first on March 7, 2020, in a 45-year-old resident of Kancheepuram.⁵ The rapid spread resulted in the World Health Organization declaring the outbreak as a Public Health Emergency of International concern on 30th January 2020, and a pandemic on 11th March 2020. The increasing and decreasing trends of infection over an extended period constitutes a wave. The number of cases in India reached a peak within 8 months (January 27 - September 18, 2020) and then gradually started to decline. When the country started to see a drop in cases amidst the first wave, and the situation had started to lighten, a second wave, which was more virulent had taken its toll upon the nation. Approximately, three lakh deaths have been linked to Covid-19 in the country as it continues to grapple with the pandemic.^{6,7}

Confirmed and reported cases of Covid-19 have a wide-ranging symptom from mild complaints, such as fever and cough, to more critical cases linked with difficulty in breathing. Some of the most familiar signs comprise cough, fever, chills, shortness of breath, unexplained loss of taste or smell, diarrhoea, muscle aches, sore throat, and headache. Signs can start as mild and turn out to be more extreme over a week, worsening if pneumonia

progresses in subjects. Roughly, 1 out of six infected people become seriously ill and create difficulty in breathing, particularly in the elderly with basic health situations.⁸⁻¹⁰

As the disease being relatively new- conditions which favour it and the health groups with increased occurrence etc is now also in a grey zone with limited evidence. On the basis of current data and clinical expertise, the elderly, particularly those in long-term care facilities, and people of any age with significant underlying medical situations are at more danger of contracting the disease. The elderly, a vulnerable population, with chronic health situations such as diabetes and cardiovascular or lung illness are not only at a greater danger of acquiring severe disease but are also at an enhanced danger of death if they become ill. People with underlying uncontrolled medical situations such as hypertension; lung, liver, and kidney disease; diabetes; cancer patients on chemo-therapy; smokers; transplant recipients; and patients taking steroids chronically are at greater risk of disease or infection.⁸ People with chronic obstructive pulmonary disease or any respiratory illnesses are also at greater danger of getting the illness into severe one. A meta analysis found that the existence of chronic obstructive pulmonary disease is linked with a nearly four fold greater risk of acquiring severe covid-19.¹¹

Different studies across the world have shown that non communicable disease including diabetes and hypertension are the most common comorbidity present among Covid-19 subjects. Also, cerebrovascular and cardiovascular conditions coexisted among such subjects and people with more than two comorbidities have a higher chance being to the worst prognostic side of the disease.^{12-17,18}

Need for the study / Justification of the study:

The current pandemic Covid-19 which started in the year of 2019 November is still continuing to pose a greatest challenge to the public along with the health system. The studies have shown that the disease affects with its severity among old age people and subjects with comorbidities. The data among deceased Covid-19 subjects is rare and also the clearcut specifications of presence of comorbidities are also not clear. So this study aimed to assess the prevalence of comorbidities and its impact among those deceased with Covid - 19.

3 AIM AND OBJECTIVES

3.1 AIM:

To estimate the prevalence of comorbidities among SARS-COV 2 deaths reported in a Tertiary Care Centre.

3.2 OBJECTIVES:

- To analyse the impact of SARS-CoV-2 infection on the most frequent comorbidities encountered amongst those who have died due to this pathogen.
- To identify the high-risk group in this pandemic and prioritising them for vaccination.
- To estimate the most prevalent comorbidity in the study population.

4 REVIEW OF LITERATURE

Review of Literature of this study is discussed under the following heads:

- A. Covid-19- clinical features and pathogenesis.
- B. Comorbidities and Covid-19 Pathogenesis.
- C. Studies related to the topic.

4.1 COVID-19- CLINICAL FEATURES AND PATHOGENESIS

First cases of COVID-19 were reported in Wuhan, China, in December 2019. By April 25, 2021, 220 countries has been affected with the virus due to its rapid spread. As of April 25, 2021, countries such as USA, Brazil, Mexico, and India (equalling >1.3million deaths and >65million infections) were most affected.^{2,3}

Currently, world is witnessing a pandemic with the emergence of SARS-CoV-2 virus, greater than the 1918–19 Spanish influenza pandemic in terms of the morbidity, mortality and economic disruptions. The widely accepted origin of virus is the animal host followed by zoonotic transfer.¹


Virus life cycle:

The virus is spread through respiratory droplets and aero-sols from person to person. Once within the body, the virus attaches to host receptors and move into host cells through endocytosis or membrane fusion.^{19,20}

The coronaviruses are made up of four structural proteins, namely,

- The Spike (S)
- Membrane (M)
- Envelop (E)
- Nucleocapsid (N) proteins

Figure 1: Life cycle of corona virus²¹



The following image represents the Inflammatory mechanism, damage of the alveolar epithelium and endothelium, and coagulopathy in COVID-19,²²

Figure 2. Inflammatory mechanism, damage of the alveolar epithelium and endothelium, and coagulopathy in COVID-19




Figure 3: Clinical spectrum of covid






Table 1. Clinical spectrum of the COVID-19

Severity of disease	Presentation
Asymptomatic	<ul style="list-style-type: none">-No clinical symptoms-Positive nasal-swab test-Normal findings in chest X-ray
Mild illness	<ul style="list-style-type: none">-Nausea, vomiting, loose stools, abdominal pain,-Fever, sore-throat, dry cough, malaise and body aches or
Moderate illness	<ul style="list-style-type: none">-Symptoms of pneumonia (persistent fever and cough) without hypoxemia-Significant lesions on high-resolution CT-chest
Severe illness	<ul style="list-style-type: none">-Pneumonia with hypoxemia($SpO_2 < 92\%$)
Critical state	<ul style="list-style-type: none">-ARDS, along with shock, encephalopathy, coagulation defects, heart failure and acute kidney injury.

The following figure represents the Pathophysiology and clinical features of COVID-19.²³


Figure 4. Pathophysiology and clinical features of COVID-19





COVID-19 (Corona Virus Disease 2019): Pathophysiology and Clinical Findings

Authors: Ryan
Brennan, Yan Yu*
Reviewers: Carol
Hank, Yonglin Ma
(EJLB)*
Stephen Vaughan*
* MD at time of
publication



4.2 COMORBIDITIES AND COVID-19



DIABETES MELLITUS

The effects of Covid-19 among diabetics vary from simple hyperglycaemia to multi organ failure.⁽²⁴⁻³⁰⁾⁽³¹⁾

- Hyperglycaemia, leading to hyper glycosylation of Angiotensin converting enzyme-2 and increased viral proliferation.
- Worsening of hyperglycaemia induces inflammation, endothelial dysfunction, and thrombosis through the generation of oxidative stress making the dys-regulation of glucose metabolism and hyper-coagulability.

- Severe infection in the individuals pre-disposed to vasculo-pathy and impaired immunity may emphasize thrombotic and ischemic problems linked with multiorgan failure and enhanced mortality rates.
- All the forms of diabetes mellitus can be characterised by abnormal signalling along pathways engaged in glucose metabolism.
- Chronic hyperglycaemia and insulin resistance contribute to vasculopathy through various mechanisms. These include abnormal signalling along the advanced glycation end products—receptors of advanced glycation end products and oxidative damage.
- In addition, metabolic abnormalities related with oxidative damage sources changes in mitochondrial expression of superoxide in endothelial cells of both large and small vessels. Over time, augmented superoxide creation mediates a cascade of epigenetic alterations that result in tenacious expression of pro-inflammatory pathways even after the normalization of blood glucose levels.
- Alterations in innate and adaptive immunity, together with abnormal cytokine responses, blockade of leukocyte recruitment, and neutrophil dys-function, are also driven by states of chronic hyperglycaemia.

Figure 5: Effects of Covid - 19 on diabetes



- can lead to increased levels of inflammatory mediators in the blood, including lipopolysaccharide, inflammatory cytokines and toxic metabolites.
- Modulation of natural killer cell activity (increased or decreased) and interferon - gamma production can increase the interstitial and/or vascular permeability for pro-inflammatory products.
- Infection with SARS-CoV-2 leads to increased reactive oxygen species production. These effects lead to lung fibrosis, acute lung damage and acute respiratory distress syndrome
- Reactive oxygen species production and viral activation of the renin–angiotensin–aldosterone system (via increased angiotensin II expression) cause insulin resistance, hyperglycaemia and vascular endothelial damage, all of which contribute to cardiovascular events, thromboembolism and disseminated intravascular coagulation.
- Infection also causes increases in the clotting components fibrinogen and D-dimer, leading to increases in blood viscosity and vascular endothelial damage, and associated cardiovascular events, thromboembolism and Disseminated intravascular coagulation.

HYPERTENSION


The changes hypertension and Covid-19 are as follows where virus induces;⁽³²⁻³⁸⁾⁽³⁹⁾


- Endothelial dysfunction- Sustained elevation of systemic pressure in the micro-vasculature leads to pre-mature aging and amplified turn-over of endothelial cells, damaging the ability of endothelium to issue endothelium-derived relaxing factors, resulting in vasoconstriction .
- Mechanical stress induced by high intra-luminal pressure on the vascular wall activates NADPH oxidase (NOX), which is the major reactive oxygen species-producing enzyme. Excessive reactive oxygen species production generates oxidative stress that leads to endothelial dysfunction.
- Oxidative stress provokes a destructive cascade recognised at the arterial wall, followed by chronic inflammation. Chronic inflammation effects in variations in the arterial wall, such as geometric vascular remodelling, increase in intima-media thickness and functional remodelling.
- **Dysregulation of Renin angiotensin system** which consists of angiotensinogen, angiotensin-generating enzymes, and angiotensin, as well as their receptors is one of the clinical implications of Covid-19 infection.
- Patients with hypertension are more disposed to a vicious interplay between Renin angiotensin system imbalance, chronic low-grade inflammation, and elevated Dipeptidyl peptidase-4 activity and expression. Dys-regulation of these biological processes may be intensified by the Covid-19 infection, giving growth to an intensified immune response that ends in tissue damage/dysfunction.
- Also, end-organ damage produced by chronic hypertension diminishes cardiovascular reserve, as arterial stiffening, endothelial dysfunction and left

ventricular hypertrophy emerges, leading to synergic courses that increase the vulnerability to know complications of Covid-19 including myocardial injury and ischemia, acute lung injury, thrombosis, acute kidney injury, ventricular arrhythmias and potentially death.

- Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers are antihypertensive drugs frequently used in clinical practice. Angiotensin converting enzyme inhibitors reduce the generation of Angiotensin II by inhibiting Angiotensin converting enzyme, whereas angiotensin II receptor blockers reduce blood pressure by blocking the binding of Angiotensin II with AT1R. Interestingly, both upregulate Angiotensin converting enzyme-2 levels. Augmented Angiotensin converting enzyme-2 levels may increase the receptors for Covid-19 infection in the lungs and heart.

Figure 6: Covid-19 and hypertension






CARDIOVASCULAR DISEASE

The pathogenesis behind it may be ⁴⁰⁻⁴⁷

- Drugs used to lessen cardio-vascular risk such as angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers have numerous effects that might influence susceptibility to or the severity of Covid-19.
- Furthermore, although the main presentation of Covid-19 is viral pneumonia, Covid-19 can also induce cardiovascular manifestations including myocardial injury, myocarditis, arrhythmias, acute coronary syndrome and thrombo-embolism.
- Medications that have been used as treatments for Covid-19 such as hydroxychloroquine and azithromycin have pro-arrhythmic effects.
- Individuals already have a variety of sub-clinical patho-physiological irregularities, such as endo-thelial dys-function and activation, platelet hyper-reactivity and tendency to coagulopathy and dys-functional immune responses, such that they are

more probable to progress systemic inflammation and thrombo-embolic problems to infection and/or increased cardio-vascular difficulties.


Figure 7: Cardiovascular disease and Covid - 19⁴⁸



MALIGNANCY

- Subjects with cancer are highly susceptible to severe acute respiratory syndrome coronavirus 2 infection.
- The vulnerability of patients with cancer to Covid-19 is affected by cancer type, staging, and therapeutics.
- Subjects with cancer who progress Covid-19 have a elevated probability of mortality. The main causes of death comprise of adult respiratory distress syndrome, septic shock, pulmonary embolism, and acute myocardial infarction. Other risk aspects such as gender, comorbidities, obesity, age, ethnicity, smoking, and various medical circumstances have been stated to have an influence on the mortality rates of subjects with Covid-19.
- Four major signalling pathways are common to both diseases, namely cytokine, type I interferon , androgen receptor , and immune checkpoint signalling.

Figure 8: Covid-19 and malignancy



4.3 STUDIES RELATED TO THE TOPIC

Koya et al in 2021 did a study to analyse the factors related to Covid-19 death in a south Indian state and to evaluate the impact of co-morbidities. The inclusion criteria was subjects among subjects who died due to Covid-19. Among the subjects, 96 percent of the cases were documented as having co-morbidities. Among those, 71 percent had several co-morbidities. Most common co-morbidities consist of diabetes- 66 percent, hypertension-54 percent, coronary artery disease 18 percent, and chronic kidney disease 15 percent. Hypothyroidism also was observed among 4 percent of subjects.⁴⁹

Asirvatham et al in 2021 did a study to assess the demographic features of subjects who due to Covid-19, the measurement of symptom duration and other factors associated with mortality. The study showed about 85% with more than one comorbidity. Diabetes was found among 62%, hypertension-49.2% and coronary artery disease 17.5%. Higher amount of comorbidities in elderly.¹⁸

Divya Goel and Sudhir Kumar in 2021 did a report of characteristics among subjects who died due to Covid in the state of Uttarakhand. The report showed diabetes as the major proportion of co-morbidity followed by kidney related illnesses, hypertension and cancer. The report showed that higher rate of mortality amongst younger women who in the age of less than 50 years.⁵⁰

Bhaskaran et al in 2021 did a study to assess features which is related to Covid-19 deaths in comparison to other causes. Older age was more strongly related with Covid-19 death than non-covid death and the same is for was male gender, deprivation, obesity, and some co-morbidities. The study showed the comorbidities distribution among Covid -19 deaths as

follows; hypertension-74.05%, chronic respiratory disease-21.09%, chronic heart disease 36.35%, with controlled diabetes-21.12%, with uncontrolled diabetes-11.35%, malignancy-16.15%, chronic liver disease 1.56%, stroke-17.21% and rheumatoid arthritis-9.04%.⁵¹

Barbu et al in 2020 did a study to evaluate the influence of SARS-CoV-2 on the most widespread co-morbidities, among Romanian people who died of Covid-19. The study assessed the number of deaths caused by Covid-19 during a particular period and its prevalence. The mean number of pre-existing comorbidities was 2.73 (1.521), with 97.4 percent of the subjects having at least one. The most prevalent comorbidities were hypertension -43.1 percent, diabetes -33.2 percent, and coronary heart disease -26.0 percent. The relative risk is calculated from the death of general population. The calculated relative risk of death due to Covid-19 among diabetes RR = 6.426 , chronic renal disease RR = 4.338, hypertension RR=3.261, chronic pulmonary disease RR = 2.615 and chronic liver disease RR = 1.577, coronary heart disease RR = 0.664 , cancer RR = 0.515 and stroke RR = 0.468.⁵²

Stoian et al in 2020 did a study analysing the relation between Covid-19 mortality and the underlying medical condition. The study was an observational, retrospective study based on Romanian official data about location, age, gender and comorbidities for Covid-19 deaths. The study showed the comorbidity status as follows; hypertension -37.5%- diabetes -35.4%, obesity -12.27% and chronic kidney disease -10.19% as well as diseases of the circulatory system -59.26% and nutritional or metabolic disorders 42.82%.⁵³

Wortham et al in 2020 did a study to assess the features of subjects who died of Covid-19 in United states. Covid-19 death is more in subjects with inherent medical conditions and in

those aged more than 65 years. In complete, the most usual medical conditions were cardiovascular disease -60.9 percent, diabetes mellitus -39.5 percent, chronic kidney disease -20.8 percent, and chronic lung disease - 9.2 percent.⁵⁴

Guan et al in 2020 did a study to estimate the risk of serious adverse consequences in subjects with Covid-19 by separating the co-morbidity status. 131 (8.2 percent) subjects reached the composite end-points like death, ICU admission and invasive ventilation. 399 (25.1 percent) reported having at least one co-morbidity. The most widespread co-morbidity was hypertension -16.9 percent, followed by diabetes -8.2 percent. In the study, 130 (8.2 percent) subjects stated having two or more co-morbidities. The hazard ratio was 1.79 among subjects with at least one co-morbidity and 2.59 among subjects with two or more co-morbidities.¹⁴

Zhou et al in 2020 did a study to assess the risk factors for mortality and a detailed clinical course of illness among people affected with Covid - 19 in China. The study showed 91 (48 percent) subjects had a co-morbidity, with hypertension being the most frequent (58 [30 percent] subjects), followed by diabetes 36 (19 percent) subjects and coronary heart disease (15 [8 percent] subjects).⁵⁵

Kumar et al in 2020 did a meta analysis to search the association between diabetes and Covid-19 mortality and severity, and to establish the occurrence of diabetes in subjects with Covid-19. The study found that diabetes to be meaningfully related with mortality of Covid-19 with a pooled odds ratio of 1.90. Diabetes was also related with severe Covid-19 with a pooled odds ratio of 2.75. The combined pooled occurrence of diabetes in subjects with Covid-19 was 9.8 percent.⁵⁶

Goyal et al in 2020 did a study to assess the clinical characteristics of subjects affected with Covid-19 in New York city. The mean age was 62.2 years with 60.6 percent of males. Among those admitted for Covid-19, 25.2 percent had diabetes and 50.1 percent had hypertension.⁵⁷

Chow et al 2020 reported about the prevalent conditions among subjects admitted with Covid-19 in United states. Among the subjects 37.6 percent patients had one or more basic health condition or risk factor. The percentage of Covid-19 subjects with at least one underlying comorbid condition was higher among those necessitating intensive care unit admission, 78 percent and those necessitating hospitalization 71 percent. The most frequently described situations were diabetes mellitus, chronic lung disease, and cardio-vascular disease.⁵⁸

Paudel in 2020 did a study to find out clinical features of Covid-19 infection and also about the co-morbidities that are related with it. The study showed that Fever was observed in 88.8 percent cases. Dry Cough in 68 percent followed by fatigue in 33 percent. Hypertension (15.8 percent) is the most usual co-morbidity followed by cardio and cerebro-vascular condition (11.7 percent).⁵⁹

5 RESEARCH QUESTION OR HYPOTHESIS

5.1 RESEARCH QUESTION:

What is the relationship between comorbidities and death among Covid-19 subjects?

5.2 NULL HYPOTHESIS:

There is no relationship between comorbidities and death among Covid-19 subjects.

5.3 ALTERNATE HYPOTHESIS:

There is a significant relationship between comorbidities and death among Covid-19 subjects.

6 METHODOLOGY

6.1 STUDY SUBJECTS:

All dead patients ,diagnosed with SARS-COV 2 based on WHO's interim guidelines
- June 2020 to June 2021.

6.2 STUDY DESIGN:

Retrospective Descriptive Study

6.3 STUDY SETTING:

Department of Internal Medicine tertiary care centre, TamilNadu.

6.4 SAMPLING PROCEDURE:

The study subjects was selected consecutively from deaths reported due to Covid-19
between June 2020 and June 2021 as reported by the Ministry of Health

6.5 INCLUSION CRITERIA:

- Deaths with confirmed RT-PCR positive result for SARS-COV-2.
- Patients with age >15 years.
- The date of admission of these patients should be within this study period.

6.6 EXCLUSION CRITERIA:

- Patients with age <15 years.
- Patients who recovered from SARS-COV-2 infection.
- RT PCR positive patients who were discharged and later expired due to other causes.

6.7 SAMPLE SIZE:

According to Koya et al study,⁴⁹ considering the prevalence of presence of diabetes mellitus among subjects who died with Covid-19 as 66% with a precision of 5% and 95% confidence interval, the sample size is calculated as

$$N = Z_{1-\alpha/2}^2 * p * (1 - p) / d^2$$

$Z_{1-\alpha/2}$ - two tailed probability for 95% confidence interval = 1.96

p (%) - prevalence of presence of diabetes mellitus among subjects who died with Covid-19 = 0.66

d (%) - precision or allowable error for presence of diabetes mellitus among subjects who died with Covid-19 = 0.05

$$N = 1.96^2 * 0.66 * (1 - 0.66) / 0.05^2$$

$$N = 344.81$$

Thus the total minimum sample size required for the study is 345. The samples have been taken between June 2020 and June 2021 which came up to 796.

6.8 STUDY PROCEDURE:

The study comprised deaths caused by COVID-19 between June 2020 and June 2021 as reported by the Ministry of Health. After applying appropriate inclusion and exclusion criteria all data is collected from information system of hospital, including demographic ,clinical ,laboratory and treatment data. The available data generally included information about the age, gender, confirmed positive, the date of death and their underlying comorbidities. All the information was anonymous, with no patient identifiers. Data regarding ethnicity or race was not included in the report. All data is cross-checked. Missing and uncertain records was excluded if which cannot be provided or clarified by involved health-care providers.

6.9 ETHICAL CONSIDERATION:

Institutional Ethical Committee approval was obtained before the start of the study.
Informed written consent was obtained from each participant.

Source of Funding: NIL

Conflict of Interest: NIL

6.10 STUDY PERIOD:

The study was done for a period of one year between June 2020 – June 2021.

6.11 STATISTICAL METHODS:

Descriptive Statistics:

1. Numerical variables like age and mean number of comorbidities are represented in mean, median, mode and standard deviation.
2. Categorical variables like gender, comorbidities description and number of comorbidities are represented in frequencies and percentages. Pie-charts and bar diagrams are used as appropriate.

Inferential Statistics:

3. When a Numerical variable is associated with the Numerical variables such as Pearson's correlation test is used after checking for normality. Here the data not followed normality, so Spearman's correlation test is used. Correlation of 'time spent in hospital' before death with respect to various factors like age, time of appearance of symptoms to admission and number of comorbidities
4. When a Categorical Variable is associated with a categorical variable, the variables are represented in both by tables and bar diagrams. For test of significance, chi-square test is used. Fischer's exact test is used when more than 20% of the cell values have expected cell value less than 5. Here the comorbidity status of the subjects [presence or absence] was taken as categorical variables and association was seen with gender and age categories.

When categorical variable like comorbidity status of the subjects [presence or absence] was associated with age , number of comorbidities and time spent in hospital before death was compared independent t test was used to find the association. Mann Whitney U test is used to find association if the variables doesn't follow normality.

5. P-values less than 0.05 were considered statistically significant.
6. Data was entered in MS excel sheet and analysed using SPSS software version 16.

7 RESULTS

Results of the study is discussed under the following headings:

DESCRIPTIVE STATISTICS

- Age distribution
- Age category distribution
- Gender distribution
- Frequency distribution of locality of deceased Covid-19 patients
- Distribution of occurrence of comorbidity
- Distribution of type of comorbidity
- Description of number of days of symptoms before Covid-19 admission
- Description of number of comorbidity category
- Description of duration of comorbidity category observed in the deceased Covid-19 patients

INFERENTIAL STATISTICS


- Comparison of age with respect to gender category in deceased Covid-19 patients.
- Comparison of comorbidity status with respect to gender in deceased Covid-19 patients
- Comparison of comorbidity status with respect to age in deceased Covid-19 patients
- Correlation of 'time spent in hospital' before death with respect to various factors in deceased Covid-19 patients.
- Comparison of duration of 'time spent in hospital before death' (in hours) between the patients with comorbidity status in deceased Covid-19 patients.

DESCRIPTIVE STATISTICS

Table 2: Age distribution among the population

Statistics	
Mean	60.35
Median	61.00
Mode	65
Std. Deviation	13.41
Minimum	16
Maximum	90

Figure 9: Age distribution among the population




The above table and figure shows the age distribution among the population. The mean (SD) of age in years among the population was 60.35(13.41) years. The minimum and maximum age in years was 16 and 90 years respectively.

Table 3. Frequency distribution of age category of deceased Covid-19 patients observed in the study.

S.No	Age group	n	%
1	≤20 years	5	0.6
2	21 – 40 years	56	7
3	41 – 60 years	326	41
4	61 – 80 years	372	46.7
5	>80 years	37	4.6

Data are expressed as n with %. Total n = 796

Figure 10: Frequency distribution of age category of deceased Covid-19 patients observed in the study.




The above table and figure showed the frequency distribution of age category among deceased Covid-19 subjects. The result showed that 372(46.7%) subjects were in the age category of 61-80 years, 326(41%) were between 41-60 years, 56(7%) between 21-40 years and 37(4.6%) between >80 years.

Table 4. Frequency distribution of gender category of deceased Covid-19 patients observed in the study.

S.No	Gender category	n	%
1	Female	242	30.4
2	Male	554	69.6

Data are expressed as n with %. Total n = 796

Figure 11: Frequency distribution of gender category of deceased Covid-19 patients observed in the study.




The above table and figure showed gender category of deceased Covid-19 patients observed in the study. The study showed 554(69.6%) subjects who deceased due to Covid-19 were males and 242(30.4%) were females.

Table 5: Frequency distribution of locality of deceased Covid-19 patients observed in the study.

S.No	Locality	n	%
1	Thanjavur	679	85.3
2	Thiruvarur	51	6.4
3	Ariyalur	23	2.9
4	Nagapattinam	15	1.9
5	Pudukottai	5	0.6
6	Trichy	4	0.5
7	Mayiladuthurai	4	0.5
8	Cuddalore	2	0.3
9	Madurai	2	0.3
10	Chennai	1	0.12
11	Erode	1	0.12
12	Karaikal	1	0.12
13	Karur	1	0.12
14	Kumabakonam	1	0.12
15	Namakkal	1	0.12
16	Pattukottai	1	0.12
17	Perambalur	1	0.12
18	Puducherry	1	0.12
19	Sivagangai	1	0.12
20	Not-known	1	0.12

Data are expressed as n with %. Total n = 796

Figure 12: Frequency distribution of locality of deceased Covid-19 patients observed in the study




The table and figure above showed the frequency distribution of locality of deceased Covid-19 patients observed in the study. The results showed that 679(85.3%) subjects were from Thanjavur, 51(6.4%) from Thiruvarur and 23(2.9%) were from Ariyalur.

Table 6: Frequency distribution of occurrence of comorbidity observed in the deceased Covid-19 patients

S.No	Comorbidity	n	%
1	Present	616	77.4
2	Absent	180	22.6

Data are expressed as n with %. Total n = 796

Figure 13: Frequency distribution of occurrence of comorbidity observed in the deceased Covid-19 patients




The above table and figure showed frequency distribution of occurrence of comorbidity observed in the deceased Covid-19 patients. The study showed that 616(77.4%) subjects had presence of co-morbidities.

Table 7: Frequency distribution of type of comorbidity observed in the deceased Covid-19 patients.

S.No	Type of comorbidity	n	%
1	Diabetes mellitus(DM)	431	70.0
2	Systemic hypertension(SHT)	334	54.2
3	Coronary artery disease(CAD)	124	20.1
4	Chronic kidney disease(CKD)	93	15.1
5	Hypothyroidism	21	3.4
6	Cerebrovascular accident(CVA)	18	2.9
7	Pulmonary tuberculosis(PTB)	11	1.8
8	Bronchial asthma	10	1.6
9	Post-CABG	8	1.3
10	Chronic obstructive pulmonary disease(COPD)	7	1.1
11	Various cancers	7	1.1
12	Road traffic accident(RTA)/Head injury	5	0.8
13	Respiratory failure	4	0.6
14	Decompensated chronic liver disease(DCLD)	4	0.6
15	Morbid obesity	4	0.6
16	Seizure disorders	4	0.6
17	Metabolic encephalopathy	3	0.5
18	Mucormycosis	3	0.5
19	Others	43	6.9

Data are expressed as n with %. Total n = 616 (180 patients did not have comorbidity)

Figure 14: Frequency distribution of type of comorbidity observed in the deceased Covid-19 patients.



The above table and figure showed the Frequency distribution of type of comorbidity observed in the deceased Covid-19 patients. The study showed Diabetes mellitus (DM) was

present for 431(70%), Systemic hypertension (SHT)334(54.2%), Coronary artery disease (CAD) 124(20.1%) and Chronic kidney disease(CKD)93(15.1%)

Table 8: Description of other comorbidity conditions observed in deceased Covid-19 patients. [n = 616]

S.No	Other comorbid conditions	n	%
1	Acute limb ischemia	1	0.16
2	SLE	1	0.16
3	Dyslipidemia	1	0.16
4	Hyperthyroidism	1	0.16
5	Post infarction failure	1	0.16
6	Necrotising fasciitis	1	0.16
7	Sepsis	1	0.16
8	Severe MR	1	0.16
9	Anaemia	2	0.32
10	Schizophrenia	1	0.16
11	Myasthenia gravis	1	0.16
12	Psychiatric disorders	2	0.32
13	Duodenal perforation	1	0.16
14	HIV	1	0.16
15	BPH	1	0.16
16	DVT	1	0.16
17	Hyperosmolar nonketotic coma	1	0.16
18	Sigmoid volvulus	1	0.16
19	Rheumatoid arthritis	1	0.16
20	Filarial limb	1	0.16
21	Operated Arnold Chiari malformation	1	0.16

22	Bicytopenia	1	0.16
23	Angina	1	0.16
24	STEMI	2	0.32
25	AWMI	2	0.32
26	Acute necrotizing pancreatitis	1	0.16
27	HCV	2	0.32
28	NSTEMI	1	0.16
29	Parkinson disease	2	0.32
30	GERD	1	0.16
31	Post stent status	1	0.16
32	DKA	2	0.32
33	Post polio sequelae	1	0.16
34	Bicuspid aortic valve	1	0.16
35	Dermatomyositis	1	0.16
36	Chronic pancreatitis	1	0.16

Data are expressed as n with %. Total n = 616 (180 patients did not have comorbidity)


The above table showed the description of other comorbidity conditions observed in deceased Covid-19 patients.

Table 9: Frequency description of number of days of symptoms before Covid-19 admission observed in the study

S.No	Duration of Covid symptoms before admission	n	%
1	0 – 7 days	718	90.2
2	8 – 14 days	66	8.3
3	15 – 21 days	11	1.4
4	>21 days	1	0.1

Data are expressed as n with %. Total n = 796

Figure 15: Frequency description of number of days of symptoms before Covid-19 admission observed in the study




The above table and figure showed the frequency description of number of days of symptoms before Covid-19 admission observed in the study. In the study showed 718(90.2%) subjects had symptoms between 0-7 days before admission. Also 66(8.3%) subjects had symptoms between 8 – 14 days and 11(1.4%) subjects had between 15- 21 days.

Table 10: Frequency description of number of comorbidity category observed in the deceased Covid-19 patients

S.No	Number of comorbidities	n	%
1	Nil	180	22.6
2	One	254	31.9
3	Two	213	26.8
4	Three	112	14.1
5	Four	33	4.1
6	Five	4	0.5

Data are expressed as n with %. Total n = 796

Figure 16: Frequency description of number of comorbidity category observed in the deceased Covid-19 patients




Above table and figure showed the frequency description of number of comorbidity category observed in the deceased Covid-19 patients. Among the subjects 180(22.6%) had nil comorbidities, 254(31.9%) had at least one comorbidity, 213(26.8%) subjects had two comorbidity and 112(14.1%) had three comorbidities. The mean(SD) of number of comorbidities among subjects with comorbidities[n=616] was 1.90(0.93).

Table 11: Frequency description of duration of comorbidity category observed in the deceased Covid-19 patients

S.No	duration of comorbidity	n	%
1	0 – 5 years	155	28.03
2	6 – 10 years	264	47.74
3	11 – 15 years	110	19.89
4	16 – 20 years	19	3.44
5	21 – 25 years	4	0.72
6	>25 years	1	0.18

Data are expressed as n with %. Total N = 553. (63 patients data – not known for duration of comorbidity)

Figure 17: Frequency description of duration of comorbidity category observed in the deceased Covid-19 patients(n=553)



The above table and figure showed the description of duration of comorbidities among the deceased Covid-19 subjects. In the study among 63 subjects the duration of comorbidity is not known. The study showed that 264(47.74%) subjects had a duration of 6-10 years, 155(28.03%) between 0-5 years, 110(19.89%) between 11-15 years and 19(3.44%) subjects had between 16-20 years.

Table 12: The distribution of hospital stay in hours duration

Statistics	In hours
Mean	127.92
Median	110
Mode	70
Std. Deviation	102.99
Minimum	3
Maximum	710

The above table showed the distribution of duration of time spent in hospital before death. The mean (SD) was 127.92(102.99) hours. The median hours was 110 hours with a minimum of 3 and maximum of 710 hours.

INFERENCE STATISTICS

Table 13. Comparison of age with respect to gender category in deceased Covid-19 patients.

S.No	Age category	Female (N=242)		Male (N=554)		Table value	df	p value
		n	%	n	%			
1	≤20 years	4	80	1	20	17.9	4	0.001*a
2	21 – 40 years	25	44.6	31	55.4			
3	41 – 60 years	105	32.2	221	67.8			
4	61 – 80 years	103	27.7	269	72.3			
5	>80 years	5	13.5	32	86.5			
Age in years mean (SD)		57(14.10)		61.82(12.83)		0.91		<0.001*b


a-Fischer's exact test expressed as frequency(%)

b- Independent t test expressed as mean(standard deviation)

*indicates $p < 0.05$ and considered statistically significant.

The table above showed the comparison of age in categories and gender, also the mean age difference between difference gender is given . The result showed that male gender was significantly older in comparison to female gender[61.82(12.83) vs. 57(14.10)] . The 269(72.3%) of male subjects who died where in the age group of 61-80 years.

Figure 18: Comparison of age with respect to gender category in deceased Covid-19 patients




The figure above showed the comparison of age categories and gender. The 269(72.3%) of male subjects who died were in the age group of 61-80 years whereas females were 103(27%).

Table 14: Comparison of comorbidity status with respect to gender in deceased Covid-19 patients

S.No	Comorbidity	Female (N=242)		Male (N=554)		Chi square value	df	P value
		n	%	n	%			
1	Absent	63	26	117	21.1	2.3	1	0.141 (NS)
2	Present	179	74	437	78.9			

Data are expressed as n with %. Fischer's exact test was used to compare the frequency between the groups. NS = Not significant.

Figure 19: Comparison of comorbidity status with respect to gender in deceased Covid-19 patients



Above table and figure showed the comparison of comorbidity status of absent and present with gender. The result showed there was no significant difference between gender in terms of comorbidity status.

Table 15: Comparison of comorbidity status with respect to age in deceased Covid-19 patients

Comorbidity	Present	Absent	Table value	p value
Age in years Mean(SD)	61.58(11.93)	56.15(16.91)	40.52	<0.001*

Data are expressed as mean(standard deviation) independent t test was used to compare the frequency between the groups.

*indicates $p < 0.05$ and considered statistically significant.

The above table shows the relation between comorbidity status and age in years. The result showed that mean(SD) age in subjects with presence of comorbidity was significantly more than those without comorbidity [61.58(11.93) vs. 56.15(16.91)]

Table 16. Comparison of Comorbid status with respect to age category in deceased Covid-19 patients.

S.No	Age category	Comorbidity present		Comorbidity absent		Table value	p value
		n	%	n	%		
1	≤20 years	1	0.2	4	2.2	48.09	<0.001*
2	21 – 40 years	25	4.1	31	17.2		
3	41 – 60 years	259	42	67	37.2		
4	61 – 80 years	303	49.2	69	38.3		
5	>80 years	28	4.5	9	5		

Fischer's exact test expressed as frequency(%)

*indicates $p < 0.05$ and considered statistically significant.

The table above showed the comorbid status with respect to age. The result shows that majority of comorbidity were present in the age group of 61-80 years 303(49.2%) and 41-60 years (259(42%)). The result was statistically significant.

Table 17: Correlation of 'time spent in hospital' before death with respect to various factors in deceased Covid-19 patients.

S.No	Correlation of 'time spent in hospital' (in hours) before death with	Spearman's coefficient	P value	Inference
1	Age in years	-0.060	0.090(NS)	No correlation
2	Number of days of symptoms before admission	0.041	0.21 (NS)	No correlation
3	Duration of comorbidity in years	-0.018	0.76 (NS)	No correlation
4	Number of comorbidities	-0.017	0.623 (NS)	No correlation

Total N = 796. Correlation was performed using spearman's correlation test. Degree and direction of association was represented using 'r' value. *indicates $p < 0.05$ and considered statistically significant. NS = Not significant.

The above table showed the correlation between time spent in hospital before death with age, number of days of symptoms before admission, duration and number of comorbidities. The result showed a nil significant correlation with the variables.

Table 18: Comparison of duration of ‘time spent in hospital before death’ (in hours) between the patients with comorbidity status in deceased Covid-19 patients.

Parameter	Comorbidity absent (N=180)	Comorbidity present (N=616)	t value	P value
	Median (interquartile range)	Median (interquartile range)		
Duration of time spent in hospital before death (in hours)	118(70, 190)	100(70,168)	5335	0.44(NS)

Data are expressed median(interquartile range). Mann Whitney U test was used to compare the median between the groups. NS = Not significant.

The table above showed comparison of duration of ‘time spent in hospital before death’ (in hours) between the patients with comorbidity status in deceased Covid-19 patients. The result showed that there was no significant association between the two variables.

8 DISCUSSION

The study was done with an objective to assess the impact of Covid-19 infection on the most frequent comorbidities encountered amongst those who have died due to this pathogen. The study also wanted to identify the high-risk group in this pandemic and prioritising them for vaccination. And also, to estimate the most prevalent comorbidity in the study population. The study was done among subjects who died due to Covid-19.

In the study the mean (SD) of age in years among the population was 60.35(13.41) years. The frequency distribution of age category among deceased Covid-19 subjects showed that 372(46.7%) subjects were in the age category of 61-80 years and 326(41%) were between 41-60 years. The gender category of deceased Covid-19 patients observed showed that 554(69.6%) subjects who deceased due to Covid-19 were males and 242(30.4%) were females. The study showed significant difference in the age of male and females [61.82(12.83) vs. 57(14.10)] .

In a study by Asirvatham et al the mean age of deceased was 62.5(13.7) years . Also males were older than females [62.8(13.6) vs 61.8(14.2)]. Majority of the deceased were males 71.4%. Also most of the deceased belonged to 60-74 years -44.5%.(18) In a study in Romania the mean (SD) age of deceased subjects was 67(13.1) years with 65.3% males.⁵³ In a study done among deceased subjects in Uttarakhand more mortality is reported among women less than 50 years.⁵⁰ In a study in United Kingdom 61.07% died due to covid19 were above the age of 80 years and 55.36% were males.⁵¹ In a study done by Koya et al among 200 deaths from Tamilnadu 73% subjects were male and median age was 64 years.⁴⁹ Wortham et al did a study in United States among deceased Covid-19 subjects of which 60.6% were male and 74.8% were aged ≥ 65 years.⁵⁴ In a study among 814 deaths due to

Covid-19 in Romania the 61.4% males where the mean age was 68.2 year. In the study 90.9% of deaths happened in above 50 years.⁵² Li et al showed that (73%) of subjects who died of Covid-19 where males.⁶⁰ Du et al found that the mean age of deceased subjects with Covid-19 was 70.2(7.7) years.⁶¹

The studies described above is almost in concordance with our study. The central tendency measures of age almost coincides in all studies. Also, all studies have shown to have a higher male preponderance in mortality. The age group of deceased subjects also showed similar patterns where most falls above 60 years. The mild disparity in demographics showed the disparity in study period, study setting and data collection procedures.

The study showed that among deceased Covid-19 patients 616(77.4%) subjects had presence of co-morbidities. The frequency description of number of days of symptoms before Covid-19 admission observed in the study showed that 718(90.2%) subjects had symptoms between 0-7 days before admission. Also 66(8.3%) subjects had symptoms between 8 – 14 days and 11(1.4%) subjects had between 15- 21 days. The median hour spent in hospital before death among subject was 110 hours. Among the subjects 180(22.6%) had nil comorbidities, 254(31.9%) had at least one comorbidity and,213(26.8%) subjects had two comorbidity The mean(SD) of number of comorbidities among subjects with comorbidities[n=616] was 1.90(0.93).

The study showed that 264(47.74%) subjects had a duration of 6-10 years and155(28.03%) between 0-5 years. In the study subjects with presence of comorbidity was significantly older than those without comorbidity[61.58(11.93) vs. 56.15(16.91)]The comorbid status with respect to age shows that majority of comorbidity were present in the age group of 61-80 years 303(49.2%) and 41-60 years (259(42%)). The correlation between time spent in

hospital before death with age, number of days of symptoms before admission, duration and number of comorbidities and comorbidity status were not significantly different

Table 19: Comorbid prevalence among deceased Covid-19 subjects in different studies.

Comorbidity	Our study	Romanian study Barbu et al ⁵²	Asiryatham et al From Tamilnadu ¹⁸	Stoian et al from Romania ⁵³	Li et al ⁶⁰	Zhou et al ⁶⁰	Du et al ⁶¹
Diabetes	70%	33.2%	62%	35.4%	13%	19%	
Systemic hypertension	54.2%	43.1%	49.2%	37.5%	47%	30%	61.9%
Chronic kidney disease	15.1%	18.9%		10.19%			
Cardiovascular disease	20.1%	26%	17.5%	59%		8%	
Chronic liver disease		9.7%					
malignancy		10.9%					
		Cerebrovascular disease					57.1%

Koya et al in 2021 showed that among the subjects, 96 percent of the cases were documented as having co-morbidities. Among those, 71 percent had several co-morbidities. Most common co-morbidities consist of diabetes- 66 percent, hypertension-54 percent, coronary artery disease 18 percent, and chronic kidney disease 15 percent. Hypothyroidism also was observed among 4 percent of subjects.⁴⁹ Asirvatham et al in 2021 showed the median time interval of hospital admission and death was 96 hours.¹⁸ Divya Goel and Sudhir Kumar in 2021 showed in the state of Uttarakhand diabetes as the major proportion of co-morbidity followed by kidney related illnesses, hypertension and cancer. The report showed that higher rate of mortality amongst younger women who in the age of less than 50 years.⁵⁰

Bhaskaran et al in 2021 showed the comorbidities distribution among Covid-19 deaths as follows; hypertension-74.05%, chronic respiratory disease-21.09%, chronic heart disease 36.35%, with controlled diabetes-21.12%, with uncontrolled diabetes-11.35%, malignancy-16.15%, chronic liver disease 1.56%, stroke-17.21% and rheumatoid arthritis-9.04%.⁵¹ Barbu et al in 2020 showed the mean number of pre-existing comorbidities was 2.73 (1.521), with 97.4 percent of the subjects having at least one. The most prevalent comorbidities were hypertension -43.1 percent, diabetes -33.2 percent, and coronary heart disease -26.0 percent.⁽⁵²⁾ Stoian et al in 2020 showed the mean (SD) number of comorbidities among the population was 2.109(1.66).⁵³

Wortham et al in 2020 showed Covid-19 death is more in subjects with inherent medical conditions and in those aged more than 65 years.⁵⁴ Guan et al in 2020 showed that 399 (25.1 percent) reported having at least one co-morbidity. The most widespread co-morbidity

was hypertension -16.9 percent, followed by diabetes -8.2 percent. In the study, 130 (8.2 percent) subjects stated having two or more co-morbidities.¹⁴

Zhou et al in 2020 showed 91 (48 percent) subjects had a co-morbidity, with hypertension being the most frequent (58 [30 percent] subjects), followed by diabetes 36 (19 percent) subjects and coronary heart disease (15 [8 percent] subjects).⁵⁵

The study thus showed similar patterns with other studies in assessing the most impactful comorbidity among subjects who deceased due to Covid-19. Mild variation in proportion can be due to disparity in the inclusion criteria, settings from which data is collected, the admission criteria of hospital or places, the sample population and the variation in the management of Covid-19 protocols across the various regions.

9 LIMITATIONS

The study was done with an objective to assess the impact of Covid-19 infection on the most frequent comorbidities encountered amongst those who have died due to this pathogen. The study also wanted to identify the high-risk group in this pandemic and prioritising them for vaccination. And also, to estimate the most prevalent comorbidity in the study population. The study was done among subjects who died due to Covid-19.

The limitations are

- The lack of data about the survivors at the same period.
- Incomplete details about few subjects.

10 RECOMMENDATIONS

The study was done with an objective to assess the impact of Covid-19 infection on the most frequent comorbidities encountered amongst those who have died due to this pathogen. The study also wanted to identify the high-risk group in this pandemic and prioritising them for vaccination. And also, to estimate the most prevalent comorbidity in the study population. The study was done among subjects who died due to Covid-19.

The recommendations are

- The risk calculation by analysing the general population death rate at the same time.
- The comorbidity impact would be more specific if compared with general population deceased subjects with similar comorbidities.
- The study period can be increased to include more subjects.

11 CONCLUSION

The study was done as a retrospective observational study among subjects who deceased due to Covid-19 in a particular period. The study was done with an objective to assess the impact of Covid-19 infection on the most frequent comorbidities encountered amongst those who have died due to this pathogen. The study also wanted to identify the high-risk group in this pandemic and prioritising them for vaccination. And also, to estimate the most prevalent comorbidity in the study population. The study was done among subjects who died due to Covid-19. The study was done among 796 deceased subjects.

The mean (SD) of age in years among the population was 60.35(13.41) years. In the study 554(69.6%) subjects who deceased due to Covid-19 were males and 242(30.4%) were females. Among the deceased Covid-19 patients showed that 616(77.4%) subjects had presence of co-morbidities. The Frequency distribution of type of comorbidity observed in the deceased Covid-19 patients showed that Diabetes mellitus (DM) was present for 431(70%), Systemic hypertension (SHT) 334(54.2%), Coronary artery disease(CAD) 124(20.1%) and Chronic kidney disease(CKD)93(15.1%).

In the study subjects presence of comorbidity was significantly older than those without comorbidity[61.58(11.93) vs. 56.15(16.91)]The comorbid status with respect to age shows that majority of comorbidity were present in the age group of 61-80 years 303(49.2%) and 41-60 years (259(42%)). The correlation between time spent in hospital before death with age, number of days of symptoms before admission, duration and number of comorbidities and comorbidity status were not significantly different.

12 SUMMARY OF RESULTS

- The mean (SD) of age in years among the population was 60.35(13.41) years. The minimum and maximum age in years was 16 and 90 years respectively.
- The frequency distribution of age category among deceased Covid-19 subjects showed that 372(46.7%) subjects were in the age category of 61-80 years, 326(41%) were between 41-60 years, 56(7%) between 21-40 years and 37(4.6%) between >80 years.
- The gender category of deceased Covid-19 patients observed showed that 554(69.6%) subjects who deceased due to Covid-19 were males and 242(30.4%) were females.
- The frequency distribution of locality of deceased Covid-19 patients observed in the study showed that 679(85.3%) subjects were from Thanjavur, 51(6.4%) from Thiruvarur and 23(2.9%) were from Ariyalur.
- The frequency distribution of occurrence of comorbidity observed in the deceased Covid-19 patients showed that 616(77.4%) subjects had presence of co-morbidities.
- The Frequency distribution of type of comorbidity observed in the deceased Covid-19 patients showed that Diabetes mellitus (DM) was present for 431(70%), Systemic hypertension (SHT) 334(54.2%), Coronary artery disease(CAD) 124(20.1%) and Chronic kidney disease(CKD)93(15.1%).

- The frequency description of number of days of symptoms before Covid-19 admission observed in the study showed that 718(90.2%) subjects had symptoms between 0-7 days before admission. Also 66(8.3%) subjects had symptoms between 8 – 14 days and 11(1.4%) subjects had between 15- 21 days.
- Among the subjects 180(22.6%) had nil comorbidities, 254(31.9%) had at least one comorbidity, 213(26.8%) subjects had two comorbidity and 112(14.1%) had three comorbidities. The mean(SD) of number of comorbidities among subjects with comorbidities[n=616] was 1.90(0.93).
- In the study among 63 subjects the duration of comorbidity is not known. The study showed that 264(47.74%) subjects had a duration of 6-10 years, 155(28.03%) between 0-5 years, 110(19.89%) between 11-15 years and 19(3.44%) subjects had between 16-20 years.
- The comparison of age in categories and gender showed that male gender was significantly older in comparison to female gender[61.82(12.83) vs. 57(14.10)]. The 269(72.3%) of male subjects who died were in the age group of 61-80 years.
- The comparison of comorbidity status of absent and present with gender showed there was no significant difference between gender in terms of comorbidity status.
- The relation between comorbidity status and age in years showed that mean(SD) age in subjects with presence of comorbidity was significantly more than those without comorbidity[61.58(11.93) vs. 56.15(16.91)]
- The comorbid status with respect to age shows that majority of comorbidity were present in the age group of 61-80 years 303(49.2%) and 41-60 years (259(42%)). The result was statistically significant.

- The correlation between time spent in hospital before death with age, number of days of symptoms before admission, duration and number of comorbidities were not significant.
- The comparison of duration of 'time spent in hospital before death' (in hours) between the patients with comorbidity status in deceased Covid-19 patients showed no significance.

13 REFERENCES

1. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Vol. 26, *Nature medicine*. 2020. p. 450–2.
2. COVID C. global cases by the center for systems science and engineering (CSSE). Johns Hopkins Coronavirus Resour Cent. 19AD;
3. Worldometer D. COVID-19 coronavirus pandemic. World Heal Organ www.worldometers.info. 2020;
4. Andrews MA, Areekal B, Rajesh KR, Krishnan J, Suryakala R, Krishnan B, et al. First confirmed case of COVID-19 infection in India: A case report. Vol. 151, *The Indian journal of medical research*. 2020. p. 490–2.
5. Bhaskar A, Ponnuraja C, Srinivasan R, Padmanaban S. Distribution and growth rate of COVID-19 outbreak in Tamil Nadu: A log-linear regression approach. *Indian J Public Health* [Internet]. 2020 Jun 1;64(6):188–91. Available from: <https://www.ijph.in/article.asp?issn=0019-557X>
6. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. *Acta Biomed*. 2020 Mar;91(1):157–60.
7. Zhang SX, Arroyo Marioli F, Gao R, Wang S. A Second Wave? What Do People Mean by COVID Waves? - A Working Definition of Epidemic Waves. *Risk Manag Healthc Policy*. 2021;14:3775–82.
8. Symptoms of COVID-19 | CDC [Internet]. [cited 2022 Aug 15]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html>

9. COVID Symptoms — Frequently Asked Questions | Johns Hopkins Medicine [Internet]. [cited 2022 Aug 15]. Available from: <https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/coronavirus-symptoms-frequently-asked-questions>
10. Coronavirus disease (COVID-19) [Internet]. [cited 2022 Aug 15]. Available from: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/coronavirus-disease-Covid-19>
11. Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Lian N, et al. The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. *J Med Virol*. 2020 Oct;92(10):1915–21.
12. Honardoost M, Janani L, Aghili R, Emami Z, Khamseh ME. The Association between Presence of Comorbidities and COVID-19 Severity: A Systematic Review and Meta-Analysis. *Cerebrovasc Dis* [Internet]. 2021;50(2):132–40. Available from: <https://www.karger.com/DOI/10.1159/000513288>
13. Fathi M, Vakili K, Sayehmiri F, Mohamadkhani A, Hajjesmaeili M, Rezaei-Tavirani M, et al. The prognostic value of comorbidity for the severity of COVID-19: A systematic review and meta-analysis study. *PLoS One*. 2021;16(2):e0246190.
14. Guan W, Liang W, Zhao Y, Liang H, Chen Z, Li Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. *Eur Respir J* [Internet]. 2020 Mar 26 [cited 2022 Aug 16];74(10):640. Available from: <https://erj.ersjournals.com/content/early/2020/03/17/13993003.00547-2020>

15. Zhou Y, Yang Q, Chi J, Dong B, Lv W, Shen L, et al. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis. *Int J Infect Dis IJID Off Publ Int Soc Infect Dis*. 2020 Oct;99:47–56.
16. Ng WH, Tipih T, Makoah NA, Verneulen JG, Goedhals D, Sempa JB, et al. Comorbidities in SARS-CoV-2 patients: A systematic review and meta-analysis. *MBio* [Internet]. 2021 Jan 1 [cited 2022 Aug 16];12(1):1–12. Available from: <https://journals.asm.org/doi/10.1128/mBio.03647-20>
17. Merga BT, Ayana GM, Raru TB, Alemu A, Negash B, Bekana M, et al. Association of Pre-Existing Comorbidities with Disease Severity Among COVID-19 Patients in Eastern Ethiopia. *Infect Drug Resist* [Internet]. 2022 Jun 1 [cited 2022 Aug 16];15:2825–34. Available from: <https://www.dovepress.com/association-of-pre-existing-comorbidities-with-disease-severity-among-peer-reviewed-fulltext-article-IDR>
18. Asirvatham ES, Sarman CJ, Saravanamurthy SP, Mahalingam P, Maduraipandian S, Lakshmanan J. Who is dying from COVID-19 and when? An Analysis of fatalities in Tamil Nadu, India. *Clin Epidemiol Glob Heal*. 2021;9:275–9.
19. Bosch BJ, Van der Zee R, De Haan CAM, Rottier PJM. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. *J Virol*. 2003;77(16):8801–11.
20. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). *Statpearls* [internet]. 2022;

21. Parasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. *Postgrad Med J* [Internet]. 2021 May 1;97(1147):312 LP – 320. Available from: <http://pmj.bmj.com/content/97/1147/312.abstract>
22. Osuchowski MF, Winkler MS, Skirecki T, Cajander S, Shankar-Hari M, Lachmann G, et al. The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. *Lancet Respir Med*. 2021 Jun;9(6):622–42.
23. COVID-19: Pathophysiology and Clinical Findings | Calgary Guide.
24. Giacco F, Brownlee M. Oxidative stress and diabetic complications. *Circ Res*. 2010 Oct;107(9):1058–70.
25. Ceriello A. Hyperglycemia and COVID-19: What was known and what is really new? Vol. 167, *Diabetes research and clinical practice*. 2020. p. 108383.
26. Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. *Can J Cardiol*. 2018 May;34(5):575–84.
27. Lim S, Bae JH, Kwon H-S, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. *Nat Rev Endocrinol*. 2021 Jan;17(1):11–30.
28. Chen J, Wu C, Wang X, Yu J, Sun Z. The Impact of COVID-19 on Blood Glucose: A Systematic Review and Meta-Analysis. *Front Endocrinol (Lausanne)*. 2020;11:574541.
29. Šestan M, Marinović S, Kavazović I, Cekinović Đ, Wueest S, Turk Wensveen T, et al. Virus-Induced Interferon- γ Causes Insulin Resistance in Skeletal Muscle and Derails Glycemic Control in Obesity. *Immunity*. 2018 Jul;49(1):164-177.e6.

30. Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R. Type 2 Diabetes and its Impact on the Immune System. *Curr Diabetes Rev.* 2020;16(5):442–9.
31. Kimberly E. Ng JPR. The Effect of COVID-19 on Patients With Diabetes. *US Pharm* [Internet]. 2020 [cited 2022 Aug 23];45(11):9–12. Available from: <https://www.uspharmacist.com/article/the-effect-of-covid19-on-patients-with-diabetes>
32. Konukoglu D, Uzun H. Endothelial dysfunction and hypertension. *Hypertens from basic Res to Clin Pract.* 2016;511–40.
33. Muhamad S-A, Ugunman A, Kumar J, Skiba D, Hamid AA, Aminuddin A. COVID-19 and Hypertension: The What, the Why, and the How. *Front Physiol* [Internet]. 2021;12. Available from: <https://www.frontiersin.org/articles/10.3389/fphys.2021.665064>.
34. Peng M, He J, Xue Y, Yang X, Liu S, Gong Z. Role of Hypertension on the Severity of COVID-19: A Review. *J Cardiovasc Pharmacol.* 2021 Nov;78(5):e648–55.
35. Castellon X, Bogdanova V. Chronic Inflammatory Diseases and Endothelial Dysfunction. *Aging Dis.* 2016 Jan;7(1):81–9.
36. Vecchione C, Carnevale D, Di Pardo A, Gentile MT, Damato A, Cocozza G, et al. Pressure-induced vascular oxidative stress is mediated through activation of integrin-linked kinase 1/betaPIX/Rac-1 pathway. *Hypertens (Dallas, Tex 1979).* 2009 Nov;54(5):1028–34.

37. Keidar S, Gamliel-Lazarovich A, Kaplan M, Pavlotzky E, Hamoud S, Hayek T, et al. Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. *Circ Res*. 2005 Oct;97(9):946–53.
38. Hanff TC, Harhay MO, Brown TS, Cohen JB, Mohareb AM. Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System? A Call for Epidemiologic Investigations. *Clin Infect Dis an Off Publ Infect Dis Soc Am*. 2020 Jul;71(15):870–4.
39. Clark CE, McDonagh STJ, McManus RJ, Martin U. COVID-19 and hypertension: risks and management. A scientific statement on behalf of the British and Irish Hypertension Society. *J Hum Hypertens* [Internet]. 2021;35(4):304–7. Available from: <https://doi.org/10.1038/s41371-020-00451-x>
40. Bean DM, Kraljevic Z, Searle T, Bendayan R, Kevin O, Pickles A, et al. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust. *Eur J Heart Fail*. 2020 Jun;22(6):967–74.
41. Pouwels KB, House T, Pritchard E, Robotham J V, Birrell PJ, Gelman A, et al. Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey. *Lancet Public Heal*. 2021 Jan;6(1):e30–8.
42. Vuille-dit-Bille RN, Camargo SM, Emmenegger L, Sasse T, Kummer E, Jando J, et al. Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors. *Amino Acids*. 2015 Apr;47(4):693–705.

43. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. *Nature*. 2020 Aug;584(7821):430–6.
44. Holman N, Knighton P, Kar P, O’Keefe J, Curley M, Weaver A, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. *lancet Diabetes Endocrinol*. 2020 Oct;8(10):823–33.
45. Hippisley-Cox J, Young D, Coupland C, Channon KM, Tan PS, Harrison DA, et al. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. *Heart*. 2020 Oct;106(19):1503–11.
46. Gu SX, Tyagi T, Jain K, Gu VW, Lee SH, Hwa JM, et al. Thrombocytopeny and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. *Nat Rev Cardiol*. 2021 Mar;18(3):194–209.
47. Arias-Fernández L, Gil-Prieto R, Gil-de-Miguel Á. Incidence, mortality, and lethality of hospitalizations for community-acquired pneumonia with comorbid cardiovascular disease in Spain (1997-2015). *BMC Infect Dis*. 2020 Jul;20(1):477.
48. Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. *Nat Rev Cardiol* 2020 179 [Internet]. 2020 Jul 20 [cited 2021 Sep 8];17(9):543–58. Available from: <https://www.nature.com/articles/s41569-020-0413-9>
49. Koya SF, Ebrahim SH, Bhat LD, Vijayan B, Khan S, Jose SD, et al. COVID-19 and Comorbidities: Audit of 2,000 COVID-19 Deaths in India. *J Epidemiol Glob Health*. 2021 Jun;11(2):230–2.

50. Goel D, Kumar S. Co-morbid conditions in COVID-19 patients in Uttarakhand state of India. *J Glob Health*. 2021;11:1–3.
51. Bhaskaran K, Bacon S, Evans SJ, Bates CJ, Rentsch CT, MacKenna B, et al. Factors associated with deaths due to COVID-19 versus other causes: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. *Lancet Reg Heal - Eur* [Internet]. 2021 Jul 1 [cited 2022 Aug 21];6:100109. Available from: <http://www.thelancet.com/article/S2666776221000867/fulltext>
52. Barbu MG, Thompson RJ, Thompson DC, Cretoiu D, Suciu N. The Impact of SARS-CoV-2 on the Most Common Comorbidities-A Retrospective Study on 814 COVID-19 Deaths in Romania. *Front Med*. 2020;7:567199.
53. Pantea Stoian A, Pricop-Jeckstadt M, Pana A, Ileanu B-V, Schitea R, Geanta M, et al. Death by SARS-CoV 2: a Romanian COVID-19 multi-centre comorbidity study. *Sci Rep* [Internet]. 2020;10(1):21613. Available from: <https://doi.org/10.1038/s41598-020-78575-w>
54. Wortham JM, Lee JT, Althomsons S, Latash J, Davidson A, Guerra K, et al. Characteristics of Persons Who Died with COVID-19 - United States, February 12-May 18, 2020. *MMWR Morb Mortal Wkly Rep*. 2020 Jul;69(28):923–9.
55. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* [Internet]. 2020 Mar 28 [cited 2021 Sep 8];395(10229):1054–62. Available from: <http://www.thelancet.com/article/S0140673620305663/fulltext>

56. Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. *Diabetes Metab Syndr.* 2020;14(4):535–45.
57. Goyal P, Choi JJ, Pinheiro LC, Schenck EI, Chen R, Jabri A, et al. Clinical characteristics of Covid-19 in New York city. *N Engl J Med.* 2020;382(24):2372–4.
58. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 - United States, February 12-March 28, 2020. *MMWR Morb Mortal Wkly Rep.* 2020 Apr;69(13):382–6.
59. Sharma P, Paudel S. A meta-analysis of 2019 novel corona virus patient clinical characteristics and comorbidities. 2020 Apr 8 [cited 2022 Aug 20]; Available from: <https://www.researchsquare.com>
60. Li K, Chen D, Chen S, Feng Y, Chang C, Wang Z, et al. Radiographic Findings and other Predictors in Adults with Covid-19. *medRxiv [Internet].* 2020; Available from: <https://www.medrxiv.org/content/early/2020/03/27/2020.03.23.20041673>
61. Du R-H, Liang L-R, Yang C-Q, Wang W, Cao T-Z, Li M, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. *Eur Respir J [Internet].* 2020;55(5). Available from: <https://erj.ersjournals.com/content/55/5/2000524>

14. ANNEXURES
I – QUESTIONNAIRE

Name:

Age:

a] < 20 years.

b] 21-40 years.

c] 41-60 years .

d] 61-80 years.

e] >80 years.

Sex:

a] male

b] female

c] others

IP number:

Locality of the deceased :

Diagnosis:

Duration of symptoms before admission:

Date of admission:

Duration of hospital stay in hours:

Date of Death:

Comorbidity:

a] present.

b] absent.

Number of comorbidities:

- a] nil.
- b]one.
- c]two.
- d]three.
- e]four.
- f]five.
- g]>five.

Type of comorbidity :

Duration of comorbidities:

- a] 0-5 years.
- b] 6-10 years.
- c]11-15 years.
- d]16-20 years.
- e]21-25 years.
- f] > 25 years.

MASTER CHART

S.no	Ip.no	Name	Age	Sex	District	DOA	Comor	DOD	O BA ADM	No comorb
1	29069	GOTHANDAPANI	84	M	TJ	05.06.20	SHTN/T2DM	06.06.20	2 D	2
2	29389	Mohamed Ali QUDUBDEEN	54	M	TJ	06.06.20	CAD/T2DM	12.06.20	2 D	2
3	33102	MATHESH	56	M	PDU	26.06.20	Dermatomyositis	27.06.20	3 D	1
4	33240	JAISHANKAR	55	M	TJ	28.06.20	T2DM/ BICUSPID AORTIC VALVE	29.06.20	10 D	2
5	34334	RAJA SULOCHANA	62	F	TJ	4.07.20	T2DM	05.07.20	7 D	1
6	34279	SESHIYA RAJ	53	M	TJ	4.07.20	NIL	08.07.20	3 D	Nil
7	34429	AHAMED BASHA	53	M	NPM	05.07.20	T2DM	08.07.20	6 D	1
8	34279	KAMARAJ	56	M	TVR	09.07.20	SHT./CAD/CKD	09.07.20	4 D	3
9	35078	VISWANATHAN	42	M	TJ	03.07.20	CAD	09.07.20	3 D	1
10	35430	HILDA	64	F	TJ	10.07.20	SHTN/T2DM/CKD	10.07.20	3 D	3
11	34124	SEKAR	58	M	TJ	03.07.20	SHTN/T2DM	11.07.20	2 D	2
12	34677	PHILOMIN RAJ	45	M	TJ	07.07.20	SHTN	13.07.20	4 D	1
13	35672	VAITHIYANADHAN	51	M	TJ	11.07.20	T2DM/CKD	13.07.20	3 D	2
14	35057	KARTHICK RAJ	34	M	TJ	12.07.20	HEAD INJURY	14.07.20	5 D	1
15	34427	KAMAL BASHA	70	M	TJ	09.07.20	T2DM	14.07.20	5 D	1
16	35572	BASKAR (PDU)	39	M	PDU	11.07.20	DCLD/VIRAL HEPATITIS	15.07.20	1 D	2
17	34322	VENKATESAN	48	M	TJ	04.07.20	RT VESTIBLUAR SCHWANNOMA /POST CRANITOMY STATUS	16.07.20	3 D	2
18	36607	SIRAJUDEEN	72	M	TJ	16.07.20	T2DM /CAD	16.07.20	1 D	2
19	Nil	SITHI MUZAMMIL	65	F	TJ	16.07.20	T2DM /SHTN/CAD	17.07.20	1 D	3
20	36302	SHANTHI	58	F	TJ	17.07.20	SHTN /MORBID OBESITY	18.07.20	4 D	2
21	33451	GUNASEKARAN	50	M	TVR	08.07.20	SHTN	19.07.20	10 D	1
22	37508	DIVYA	17	F	TJ	19.07.20	NIL	20.07.20	2 D	Nil
23	34051	MOHAN	67	M	TJ	03.07.20	SHTN/T2DM	22.07.20	7 D	2
24	37488	RAMEEJA BEEVI	63	F	NPM	19.07.20	SHTN/T2DM	22.07.20	7 D	2
25	38712	MOHAMED SULTHAN	49	M	TJ	24.07.20	SHTN/T2DM/CKD	27.07.20	4 D	3
26	39212	RAGAVASRI	23	F	AYR	25.07.20	NIL	27.07.20	1 D	Nil
27	38257	RAMALINGAM	77	M	TJ	22.07.20	SHTN/CAD	27.07.20	1 D	2
28	39325	AANDI	54	M	TJ	29.07.20	CKD	29.07.20	3 D	1
29	39544	HAJA MOIDEEN	55	M	TJ	27.07.20	NIL	29.07.20	1 D	Nil
30	36214	RAVI	50	M	AYR	26.07.20	TB/SHTN/DM/BA	29.07.20	3 D	4
31	37570	SUGUMARAN	69	M	TJ	19.07.20	T2DM/BA	29.07.20	4 D	2
32	39360	VALARMATHI	55	F	TJ	26.07.20	SHTN/T2DM/CAD/CKD	29.07.20	3 D	4

33	39742	VENKATA SUBRAMANIYAN...	45	M	TJ	28.07.20	POST POILO SEQUELAE/ CAD	29.07.20	3 D	2
34	39263	SEKAR	52	M	TJ	27.07.20	MORBID OBESE	30.07.20	1 D	1
35	39725	SHEIK DAWOOD	58	M	TJ	28.07.20	SHTN/T2DM	01.08.20	2 D	2
36	40210	ANBUMANI	59	M	TJ	28.07.20	NIL	01.08.20	2 D	Nil
37	37525	JEEVA RAJAN	40	M	TJ	19.07.20	NIL	01.08.20	1 D	Nil
38	40317	LALITHA	65	F	TJ	30.07.20	PTB	03.08.20	2 D	1
39	Nil	MAHENDHIRAN	52	M	AYR	01.08.20	NIL	03.08.20	4 D	Nil
40	40716	NEELAKANDAN	52	M	TJ	01.08.20	T2DM	03.08.20	10 D	1
41	40109	SIVAGNANADASAN	59	M	TJ	29.07.20	T2DM	03.08.20	7 D	1
42	Nil	TAMILSELVAN	70	M	TJ	01.08.20	T2DM/SHTN	03.08.20	1 D	2
43	Nil	MANICKAM	74	M	PDU	04.08.20	NIL	04.08.20	3D	Nil
44	40201	NATARAJAN	75	M	TJ	01.08.20	NIL	04.08.20	2 D	Nil
45	40714	LAKSHMI	73	F	TJ	01.08.20	T2DM/SHTN/BA	05.08.20	10 D	3
46	40357	MARIYAPPAN	59	M	TJ	01.08.20	SHTN /T2DM	05.08.20	15 D	2
47	Nil	RATHINAMALA	64	F	TJ	03.08.20	T2DM /SHTN /BA	05.08.20	5 D	3
48	41283	PRAGADEESWARA N	36	M	TJ	04.08.20	SHTN /CKD	05.08.20	4 D	2
49	Nil	DEEPAK	30	M	TJ	03.08.20	T2DM	06.08.20	4 D	1
50	421	KADHAR HUSSAIN	80	M	TVR	07.08.20	T2DM/SHTN/CAD	07.08.20	10 D	3
51	Nil	PALANIYANDI	67	M	TJ	01.08.20	T2DM /SHTN/CAD	07.08.20	3 D	3
52	40960	RAMJAN BEGAM	28	F	TVR	03.08.20	NIL	07.08.20	3 D	Nil
53	41354	RAJAM	84	F	TJ	04.08.20	T2DM /SHTN/CKD	07.08.20	2 D	3
54	39590	BAHRURUDEEN	65	M	TJ	27/07/20	T2DM	08.08.20	7 D	1
55	Nil	MANOHARAN	64	M	TJ	06.08.20	NIL	08.08.20	3 D	Nil
56	42119	ABDUL HANIFA	58	M	TJ	07.08.20	SHTN/CAD	08.08.20	0 D	2
57	31500	SURESH BABU	45	M	TJ	30/07/20	NIL	08.8.20	2 D	Nil
58	41596	JENUVA	55	F	TJ	05/08/20	SHTN/T2DM	08.08.20	5 D	2
59	36741	VALLIYAMMAL	70	F	PDU	09.08.20	NIL	09.08.20	2 D	Nil
60	42513	JEYARAMAN	83	M	TJ	09.08.20	NIL	09.08.20	2 D	Nil
61	42064	THAIYUP	61	M	TJ	07.08.20	SHTN/CAD	09.08.20	4 D	2
62	42066	KULANTHAI	60	F	TJ	07.08.20	T2DM	09.08.20	7 D	1
63	42189	KAMAL BATCHA	67	M	TJ	02.08.20	SHTN /T2DM	10.08.20	7 D	2
64	42804	PICHA MUTHU	57	M	AYR	10.08.20	CAD	10.08.20	7 D	1
65	42793	SUDHAMARY	55	F	TJ	10.08.20	SHTN	10.08.20	3D	1
66	42298	ANBALAGAN	52	M	TJ	08.08.20	T2DM/SHTN	10.08.20	3 D	2
67	41710	GNANASEKARAN	82	M	TJ	06.08.20	NIL	11.08.20	5 D	Nil
68	41195	PRAKASAM	58	M	TJ	04.08.20	SHTN/T2DM	11.08.20	2 D	2
69	41864	RADHAKRISHNAN	74	M	TJ	06.08.20	T2DM	11.08.20	2 D	1

70	42524	SYED SAHIB PIRAN	63	M	TJ	12.08.20	NIL	12.08.20	7 D	Nil
71	41561	AYYAKANNU	55	F	AYR	05.08.20	T2DM/SHTN/CAD/CKD/DKA	12.08.20	3 D	5
72	41196	NATARAJAN	60	M	TJ	04.08.20	NIL	12.08.20	3 D	Nil
73	27913	MUTHUPAANDI	33	M	SVGA	05.08.20	CP ANGLE TUMOR/POST VP SHUNT	12.08.20	7 D	2
74	42554	ELANGO VAN	58	M	TJ	09.08.20	T2 DM/SHTN/CKD	12.08.20	7 D	3
75	41404	THIYAL NAYAGI	50	F	TJ	05.08.20	T2DM/HYPOTHYROID	13.08.20	3 D	2
76	42646	MANIMEGALAI	45	F	TJ	13.08.20	T2DM/SHTN	13.08.20	2 D	2
77	43057	NATARAJAN	75	M	TJ	11.08.20	NIL	13.08.20	3D	Nil
78	42060	NATARAJAN	70	M	TJ	07.08.20	NIL	14.08.20	2 D	Nil
79	41094	GANESAN	58	M	TJ	03.08.20	NIL	14.08.20	4 D	Nil
80	42565	SRINIVASAN	63	M	TJ	12.08.20	SHTN/T2DM/CAD	14.08.20	2 D	3
81	40342	GOPALASAMY	70	M	TJ	30.07.20	SHTN /T2 DM /CAD	15.08.20	3 D	3
82	42805	UBER	59	M	TJ	11.08.20	NIL	16.08.20	5 D	Nil
83	41609	SAMPATH	62	M	TJ	05.08.20	SHTN	16.08.20	5 D	1
84	40450	DHANABAL	62	M	AYR	31.07.20	CAD /OLD PTB CAT I DEFAULTER	17.08.20	2 D	2
85	42842	JOHN KENNEDY	59	M	NPM	10.08.20	SHTN /HYPOTHYROIDISM	17.08.20	7 D	2
86	43300	ABDULV RASAK	50	M	CUPJ	13.08.20	SHTN /T2 DM	17.08.20	1 D	2
87	41660	MANOHARAN	65	M	TJ	03.08.20	SHTN	18.08.20	3 D	1
88	427418	MANIMOZHI	55	F	AYR	15.08.20	CKD	18.08.20	Nil	1
89	43964	DR.ANGAMUTHU	86	M	NPM	16.08.20	T2 DM / CAD	19.08.20	Nil	2
90	43831	MUTHULAKSHMI	65	F	TJ	15.08.20	T2DM/SHTN/BA	19.08.20	3 D	3
91	42475	GNANAM	73	F	TJ	08.08.20	T2DM/SHTN/OLD PTB	20.08.20	4 D	3
92	42911	SURENDRAN	55	M	TJ	19.08.20	SHTN	20.08.20	7 D	1
93	43817	MAHALAKSHMI	75	F	TJ	15.08.20	T2DM/SHTN	20.08.20	7 D	2
94	44505	PANEERSELVAM	72	M	TJ	19.08.20	T2DM/SHTN/HYPOTHYROID	20.08.20	5 D	3
95		SIMEON	56	M	TJ	17.08.20	T2DM	20.08.20	7 D	1
96	42727	VILVENDHAN	69	M	AYR	15.08.20	T2DM/CAD	20.08.20	3 D	2
97	44425	GANESH	65	M	TVR	18.08.20	CAD / CKD	20.80.20	7 D	2
98	43866	GOVINDARAJ	68	M	TJ	16.08.20	T2DM/SHTN/CAD/CKD	20.08.20	3 D	4
99	40781	SIVAJI PRABHU	31	M	NPM	01.08.20	RTA/HIE	21.08.20	3 D	2
100	42499	CHLLAMURUGAN	55	M	TJ	11.08.20	T2DM/SHTN/CAD	21.08.20	2 D	3
101	44488	SAMKOIL	48	M	TJ	19.08.20	T2DM/SHTN/CKD	21.08.20	7 D	3
102	42845	SATHYAVENI	65	F	TJ	19.08.20	T2DM	21.08.20	3 D	1
103	42830	BALAKRISHNAN	64	M	TJ	17.08.20	T2DM/SHTN/CAD/ POST STENT	21.08.20	7 D	4
104	42841	MOHAN KUMAR	62	M	TJ	18.08.20	T2DM/SHTN/CKD V	21.08.20	7 D	3
105	Nil	KARUNAKARAN	56	M	TJ	19.08.20	SHTN	22.08.20	2 D	1
106	42940	GANDARAJ	65	M	TJ	20.08.20	SHTN	23.08.20	10 D	1

107	43698	SUNDAR	49	M	TJ	15.08.20	T2DM	24.08.20	4 D	1
108	44656	SELVAM	54	M	NPM	19.08.20	T2DM/SHTN	24.08.20	3 D	2
109	44151	SYED MUBARAK	68	M	NPM	17.08.20	T2DM/SHTN/CAD	24.08.20	1 D	3
110	44142	VENKATAPERUMAL	77	M	TJ	17.08.20	T2DM	24.08.20	3 D	1
111	42864	SEKILAR	60	M	TJ	13.08.20	T2DM	24.08.20	7 D	1
112	42795	SUNDARAJAN	45	M	TJ	17.08.20	NIL	24.08.20	7 D	Nil
113	42962	RAJAM	82	F	TVR	20.08.20	T2DM/ SHTN/CKD IV	24.08.20	7 D	3
114	42987	THANGAVEL	65	M	TJ	21.08.20	GERD	25.08.20	7 D	1
115	42644	PANDIAN	72	M	TJ	13.08.20	CKD V	26.08.20	2 D	1
116	45633	REGUPATHY	77	M	TVR	25.08.20	SHTN/ T2DM/BA	26.08.20	10 D	3
117	42851	KEERTHIKA	26	F	TJ	18.08.20	NIL	27.08.20	4 D	Nil
118	43325	KUPPUSAMY	80	M	TJ	27.08.20	CAD	27.08.20	2 D	1
119	43185	KARUPAIYAN	70	M	TJ	25.08.20	SHTN/ CKD	28.08.20	3 D	2
120	42924	SARAVANAN	34	M	AYR	19.08.20	SHTN/CKD	28.08.20	5 D	2
121	43138	RAJENDRAN	57	M	TJ	23.08.20	T2 DM /CKD	29.08.20	10 D	2
122	43127	ZUNAITHA BEGAM	73	F	TJ	23.08.20	NIL	29.08.20	7 D	Nil
123	43243	MADHAVI	58	F	TJ	26.08.20	NIL	29.08.20	5 D	Nil
124	45559	SARANGADHARAN	84	M	TVR	24.08.20	T2DM /SHTN	29.08.20	5 D	2
125	45860	RAHUMAN	83	M	TVR	26.08.20	PARKINSONS DISEASE	30.08.20	5 D	1
126	46242	MURUGESAN	60	M	TJ	28.08.20	NIL	31.08.20	4 D	Nil
127	46461	CLEMENT	70	M	NPM	29.08.20	SHTN /OLD CVA	31.08.20	4 D	2
128	43385	RAJESWARI	73	F	TJ	29.08.20	T2 DM /SHTN /CKD	31.08.20	2 D	3
129	46917	VISHVALINGAM	48	M	TJ	31.08.20	DCLD/HEPATIC FAILURE	31.08.20	4 D	2
130	43171	SELVARAJ	70	M	TJ	24.08.20	MULTIPLE MYELOMA /POST CHEMOTHERAPY	26.08.20	4 D	2
131	43163	NAHOORKANI	55	M	TVR	24.08.20	T2 DM	01.09.20	3 D	1
132	43364	JEYALAKSHMI	76	F	TVR	28.08.20	T2 DM /SHTN	02.09.20	14D	2
133	46604	RANI	58	F	TJ	29.08.20	SHTN /T2 DM /CAD/ CKD STAGE III	02.09.20	4 D	4
134	41380	RAMASAMY	60	M	TJ	04.08.20	CKD	02.09.20	3 D	1
135	46048	SUBRAMANI	65	M	TJ	27.08.20	CKD STAGE 5	02.09.20	2 D	1
136	43318	PARAMASIVAM	75	M	TVR	27.08.20	SHTN /T2DM	02.09.20	7 D	2
137	43289	MALARKODI	56	F	TJ	27.08.20	SHTN /T2DM /HYPOTHYROIDISM	03.09.20	2 D	3
138	43488	CHANDRASEKARAN	76	M	TJ	30.08.20	T2DM,SHTN,CKD,CAD	03.09.20	2 D	4
139	43567	SELVI	45	F	TJ	02.09.20	SHTN/HYPOTHYROID	04.09.20	2 D	2
140	43415	KAMARAJ	66	M	TJ	29.08.20	T2DM,CAD	04.09.20	3D	2
141	46193	SHAKTHIVEL	69	M	TJ	27.08.20	CAD	04.09.20	3D	1
142	45400	KAMALUDEEN	54	M	TJ	24.08.20	CAD	04.09.20	1 D	1
143	46148	VUJYALAKSHMI	60	F	TJ	27.08.20	SHTN,T2DM,CAD,NSTEMI,OLD CVA	05.09.20	10 D	5

144	43642	POONKULALI	53	F	AYR	03.09.20	SHTN,T2DM,CKD STAGE 5	05.09.20	2 D	3
145	43681	NARAYANAN	72	M	AYR	04.09.20	T2DM,CAD	06.09.20	3 D	2
146	45925	MANOHAR	45	M	TJ	26.08.20	SHTN,CKD STAGE 5,HCV+,IRREDUCIBLE UMBILICAL HERNIA	06.09.20	7 D	4
147	47945	RASAIYAN	64	M	NPM	05.09.20	UNCONTROLLED T2DM,CAD	06.09.20	7 D	2
148	47593	KANNAN	65	M	TJ	03.09.20	ACUTE ON CKD /T2DM /UREMIC ENCEPALOPATHY	06.09.20	8 D	3
149	43338	MADHURAVALLI	72	F	TJ	28.08.20	T2 DM /SHTN	07.09.20	9 D	2
150	43702	RAMALINGAM	55	M	AYR	04.09.20	T2 DM /SHTN /CKD	07.09.20	9 D	3
151	47390	JEYABALAN	66	M	TJ	02.09.20	SHTN /CAD /CKD	08.09.20	2D	3
152	48363	KALIYAMOORTHY	70	M	TJ	07.09.20	T2 DM /SHTN /CKD	08.09.20	7 D	3
153	48079	SHANMUGAM	72	M	NPM	06.09.20	T2 DM /CKD	08.09.20	1D	2
154	48806	MAHALAKSHMI	23	F	TJ	08.09.20	ACUTE NECROTISING PANCREATITIS	09.09.20	3 D	1
155	45951	MALARKODI	53	F	TJ	26.08.20	T2 DM /SHTN /CAD	09.09.20	3 D	3
156	48025	MARIA SUSAI	90	M	TJ	05.09.20	OLD TB	09.09.20	3 DATYS	1
157	40639	RAJENDRAN	47	M	TJ	01.08.20	NIL	09.09.20	5 D	Nil
158	48519	KAMALA	70	F	TJ	08.09.20	SHTN /CAD	09.09.20	10 D	2
159	48967	VIJAYA	65	F	TJ	09.09.20	SHTN	11.09.20	4 D	1
160	48950	MARIYAMBHEEVI	50	F	TJ	09.09.20	CAD	13.09.20	7 D	1
161	49172	APPAVU	63	M	TJ	10.09.20	CKD	13.09.20	7 D	1
162	48994	SARBUDEEN	55	M	TJ	09.09.20	T2 DM /SHTN	13.09.20	7 D	2
163	47931	RAMACHANDRAN	60	M	TJ	05.09.20	CAD	13.09.20	3 D	1
164	48237	PARAMASIVAM	78	M	TJ	06.09.20	NIL	14.09.20	7 D	Nil
165	49022	RAMAIYAN	75	M	TJ	09.09.20	NIL	14.09.20	7 D	Nil
166	49614	GANESAN	69	M	TJ	12.09.20	T2 DM /OLD PTB	14.09.21	3D	2
167	49927	VIJAYARAGAVAN	52	M	TJ	13.09.20	T2DM	14.09.20	NIL	1
168	49703	RAMANUJAM	90	M	TJ	12.09.20	NIL	14.09.21	NIL	Nil
169	43598	BANUMATHY	65	F	TJ	31.08.20	T2 DM /SHTN	16.09.20	ONE	2
170	48963	RAJENDRAN	67	M	TJ	09.09.20	SEIZURE DISORDER	16.09.20	NIL	1
171	489984	RAMAIYAN	81	M	TJ	13.09.20	NIL	16.09.20	2 D	Nil
172	50729	JOHN MENTOSA	62	M	TJ	16.09.20	T2 DM	16.09.20	NIL	1
173	50402	THIRULOGACHANDAR	46	M	TPJ	15.09.20	T2DM /SHTN	16.09.20	3 D	2
174	50801	KRISHNAKUMARI	63	F	TPJ	16.09.20	SHTN	17.09.20	7 D	1
175	49767	SELVARAJ	58	M	TJ	12.09.20	NIL	17.09.20	3 D	Nil
176	48727	MAHALAKSHMI	61	F	TJ	08.09.20	NIL	17.09.20	NIL	Nil
177	44388	THANGAPAPPA	55	F	TJ	18.08.20	SHTN /HYPOTHYROIDISM / CKD	18.09.20	3 D	3
178	50000	VENU	36	F	MDU	13.09.20	NIL	18.09.20	5 D	Nil
179	51460	RAMASAMY	69	M	TJ	18.09.20	SHTN / T2DM /MORBID OBESITY	20.09.20	5 D	3

180	50036	ADAIKALAM	51	M	TJ	13.09.20	T2 DM / SHTN	20.09.20	5 D	2
181	51238	RAMALINGAM	79	M	TJ	17.09.20	T2 DM / SHTN/ CAD	20.09.20	2 D	3
182	51555	JANAKIRAMAN	75	M	TJ	18.09.20	T2 DM /SHTN	21.09.20	10D	2
183	51998	SELVARAJ	50	M	TJ	20.09.20	T2 DM	22.09.20	2 D	1
184	50836	GANDHI	60	M	TJ	16.09.20	NIL	22.09.20	10 D	Nil
185	51549	BABY	84	F	TJ	18.09.20	SHTN	22.09.20	10D	1
186	51561	SENTAMIL SELVAN	51	M	TJ	20.09.20	T2 DM / CKD	23.09.20	2 D	2
187	52138	RENGARAJ	57	M	TJ	21.09.20	T2 DM /SHTN / CKD STAGE V	23.09.20	4 D	3
188	48507	SHANKAR	58	M	TJ	08.09.20	T2DM /SHTN /CAD	23.09.20	1 D	3
189	52728	PETER PANDIYAN	58	M	TJ	22.09.20	SHTN /T2DM /CAD	24.09.20	2 D	3
190	52409	ACHIYAMMAL	45	F	TVR	21.09.20	NIL	24.09.20	2 D	Nil
191	51421	SWAMINATHAN	55	M	TJ	18.09.20	T2 DM	24.09.20	1 D	1
192	52680	MEHARAJ BEGAM	55	F	TJ	22.09.20	CAD / ACS / AWMI	24.09.20	10 D	2
193	52175	ANTONY RAJ	50	M	TJ	21.09.20	T2DM /SHTN /CKD	24.09.20	7 D	3
194	53044	KASINATHAN	80	M	TJ	23.09.20	T2 DM	24.09.20	1 D	1
195	50699	DHANALAKSHMI	24	F	TJ	15.09.20	NIL	24.09.20	8 D	Nil
196	50434	LIYAKATH ALI	67	M	TJ	15.09.20	SHTN /T2 DM	24.09.20	3 D	2
197	52582	VUJAYA	52	F	TJ	22.09.20	T2 DM /CHRONIC PANCREATITIS	25.09.20	3 D	2
198	51752	SUNDHARARAJAN	54	M	TJ	19.09.20	NIL	25.09.20	3 D	Nil
199	51736	NATHARSHA	65	M	TJ	19.09.20	T2DM,SHTN	25.09.20	2 D	2
200	53314	DR.CHINNASAMY	69	M	TJ	24.09.20	T2 DM /SHTN /CAD	24.09.20	2 D	3
201	51545	UMARANI	37	F	NPM	18.09.20	NIL	25.09.20	1 D	Nil
202	52235	PARVATHY	57	F	TJ	21.09.20	T2DM, MUCORMYCOSIS	25.09.20	4 D	2
203	53046	SIVANESAN	67	M	TJ	23.09.20	SHTN	25.09.20	10 D	1
204	52774	SUMATHI	52	F	TJ	18.09.20	T2DM,SHTN	25.09.20	7 D	2
205	51378	MURUGESAN	54	M	TJ	18.09.20	HYPOTHYROIDISM	26.09.20	4 D	1
206	52365	LAKSHMANAN	75	M	TJ	21.09.20	T2 DM	26.09.20	7 D	1
207	54033	RAVENDRAN	65	M	TJ	27.09.20	T2 DM	27.09.20	2 D	1
208	53160	ANDAL	63	F	TJ	24.09.20	SHTN,T2DM	27.09.20	4 D	2
209	52101	ALAMELU INDIRA	53	F	TJ	20.09.20	T2DM,SHTN	27.09.21	7 D	2
210	53856	THANAMANI	67	F	TVR	26.09.20	NIL	27.09.20	2 D	Nil
211	47571	MAHENDRAN	40	M	TVR	03.09.20	UNKNOWN PRIMARY WITH SECONDARIES	28.09.20	4 D	1
212	54048	MATHIVANAN	57	M	TJ	27.09.20	T2 DM	28.09.20	3 D	1
213	53564	SAROJA	65	F	TJ	25.09.20	NIL	28.09.20	3 D	Nil
214	54613	MANI	65	M	TJ	29.09.20	T2 DM	29.09.20	3 D	1
215	54029	MOHAN	65	M	TJ	27.09.20	T2DM /SHTN /POST CABG	29.09.20	1 WEEK	3
216	54103	RAVI	50	M	TJ	27.09.20	T2DM /CKD	29.09.20	3 D	2
217	54074	CHANDRASEKARAN	67	M	TJ	27.09.20	T2 DM /SHTN /CAD	30.09.20	1 D	3

218	54044	GOVINDHAKONAR	65	M	TJ	27.09.20	NIL	01.10.20	1 WEEK	Nil
219	54404	GOVINDHAN	72	M	TJ	28.09.20	T2 DM /SHTN /CAD	01.10.20	5 D	3
220	54240	CHINNAPPAN	74	M	TJ	27.09.20	SHTN	01.10.20	3 D	1
221	54574	PALANISAMY	65	M	TJ	28.09.20	T2DM/CKD/STAGE V	2.10.20	7 D	3
222	54848	KARUPPAYAN	70	M	AYR	29.09.20	CKD	03.10.20	7 D	1
223	55948	JABHARATHU NESHA	55	F	TJ	03.10.20	T2DM	03.10.20	10 D	1
224	55560	SELVAM	50	M	TJ	02.10.20	NIL	05.10.20	14 D	Nil
225	56052	NATARAJAN	72	M	TJ	04.10.20	SHTN /CAHD	06.10.20	3 D	2
226	56297	SARAVANAN	54	M	TJ	05.10.20	T2 DM /SHTN	06.10.20	3 D	2
227	55371	PALANIVEL	57	M	TJ	01.10.20	T2DM/SHTN	07.10.20	3 D	2
228	56662	MANOHAR	58	M	TJ	06.10.20	SHTN /T2DM	08.10.20	3 D	2
229	56988	ANSARI	68	M	TJ	07.10.20	CAD/CKD	10.10.20	3 D	2
230	56362	BALAKRISHNAN	80	M	NPM	05.10.20	T2DM /CAD	10.10.20	3 D	2
231	57720	RANGACHARY	85	M	TJ	10.10.20	SHTN /T2DM	11.10.20	7 D	2
232	57662	KALIYAMOORTHY	69	M	AYR	10.10.20	NIL	11.10.20	3 D	Nil
233	56987	NAMACHIVAYAM	72	M	TJ	07.10.20	T2DM	12.10.20	3 D	1
234	52115	SUDHA	29	F	AYR	20.09.20	NIL	13.10.20	5 D	Nil
235	57238	RAVIKUMAR	50	M	TJ	08.10.20	NIL	13.10.20	3 D	Nil
236	57880	CHINNAPONNU	70	F	AYR	11.10.20	SHTN /CAD/ CKD STAGE 4	13.10.20	5 D	3
237	58159	DURAI	62	M	TJ	12.10.20	T2 DM /CAD	14.10.20	7 D	2
238	57737	KALIYA PERUMAL	80	M	TJ	10.10.20	T2DM / SHTN	15.10.20	7 D	2
239	56956	MALARKODI	54	F	TJ	04.10.20	T2DM /SHTN	15.10.20	3 D	2
240	58869	PARVEEN BANU	41	F	TVR	15.10.20	T2DM /SHTN / CAD /BA	16.10.20	5 D	4
241	57501	RAVICHANDRAN	50	M	TJ	09.10.20	T2DM	16.10.20	5 D	1
242	58675	RAJESWARI	61	F	TJ	14.10.20	T2DM	16.10.20	5 D	1
243	59399	RAVICHANDRAN	56	M	TJ	18.10.20	T2DM /SHTN /OLD CVA	19.10.20	5 D	3
244	58648	YAHAYA	74	M	TJ	14.10.20	T2DM / SHTN / CAD /POST CABG	19.10.20	5 D	4
245	58620	SIVABAKKIYAM	65	F	TJ	14.10.20	SHTN	20.10.20	5 D	1
246	57814	MANIMEGALAI	55	F	TVR	11.10.20	CKD5/SHTN/SEVERE ANEMIA	21.10.20	4 D	3
247	59416	RAMADOSS	70	M	TVR	18.10.20	T2DM	21.10.20	2 D	1
248	59765	JOTHI	48	F	AYR	19.10.20	T2DM	21.10.20	5 D	1
249	59803	SARAVANAN	42	M	TJ	20.10.20	SHTN / CKD STAGE V /POST RENAL TRANSPLANT	22.10.20	5 D	3
250	60119	SANDHANA KRISHNAN	70	M	TJ	21.10.20	CAD	22.10.20	2 D	1
251	60029	SELVARAJ	70	M	AYR	20.10.20	T2DM / RHINO ORBITAL MUCORMYCOSIS	22.10.20	5 D	2
252	59449	DHARMAN	75	M	TVR	18.10.20	NIL	24.10.20	2 D	Nil

253	61174	ABDUL AZIZ	79	M	TVR	25.10.20	SHTN	27.10.20	2 D	1
254	61151	SURESH BABU	53	M	TJ	25.10.20	SHTN/ T2DM /CKD STAGE V	27.10.20	2 D	3
255	61318	MOHAN	65	M	MV	26.10.20	T2DM /DIFFUSE LARGE B CELL LYMPHOMA	27.10.20	2 D	2
256	61384	PANDIYAN	51	M	TJ	26.10.20	NIL	28.10.20	7 D	Nil
257	61620	JEYAPANDIYAN	65	M	TJ	27.10.20	T2DM	28.10.20	4 D	1
258	61657	NARAYANASAMY	76	M	TVR	27.10.20	NIL	29.10.20	2 D	Nil
259	60558	BANUMATHI	55	F	TJ	22.10.20	NIL	30.10.20	1D	Nil
260	62331	JAYAKUMAR	54	M	PTK	30.10.20	SHTN,ABDOMINAL TB	3.11.20	7 D	2
261	59267	MAYILAMBAL	55	F	AYR	17.10.20	NIL	04.11.20	12 D	Nil
262	61948	SOPHYA	21	F	TJ	29.10.20	NIL	06.11.20	5 D	Nil
263	63584	SAKTHIVEL	75	M	TJ	05.11.20	T2DM /SHTN / OLD PTB	10.11.20	7D	3
264	63266	THIYAGARAJAN	62	M	TJ	03.11.20	T2DM/SHTN/CKD	11.11.20	10 D	3
265	63883	GOPALAKRISHNAN	53	M	TJ	06.11.20	T2DM/SHTN	12.11.20	3 D	2
266	66292	KATHIRESAN	45	M	TJ	17.11.20	SHTN	24.11.20	2 D	1
267	67262	KULANTHAIYAMMAL	63	F	TJ	21.11.20	T2DM/SHTN	23.11.20	2 D	2
268	68207	BALAKRISHNAN	70	M	TVR	27.11.20	T2DM/SHTN/CKD	29.11.20	5 D	3
269	65963	THIRUGYANANAM	53	M	TJ	16.11.20	T2DM/CAD/CKD	29.11.20	9 D	3
270	72430	RAVI	42	M	AYR	16.12.20	NIL	20.12.20	4 D	Nil
271	73183	GOPALAKRISHNAN	64	M	TJ	20.12.20	CKD	23.12.20	2 D	1
272	74488	THANIKACHALAM	71	M	MV	26.12.20	DM/CAD/CKD/OLD AWTI	31.12.20	3 D	4
273	6539	FATHURNISHA BEEVI	65	F	TJ	27/01/21	DM/CAD/SHTN	29.01.21	2 D	3
274	1494	ARIFA BEEVI	67	F	TJ	07.01.21	DM/SHTN/CAD/COPD/CKD	07.01.21	9 D	5
275	Nil	CHELLAKANNU	57	F	TJ	07.01.21	OLD PTB/CKD	08.01.21	4 D	2
276	8836	PRIYADHARSHINI	20	F	TVR	05.02.21	Nil	8.2.21	3 D	Nil
277	9079	ANTHONY PITCHAI	65	M	TJ	6.2.21	DM/SHTN/CAD/post angioplasty	10.2.21	3 D	4
278	128	MEHARAJ KANI	60	F	TVR	12.02.21	DM/SHTN	12.02.21	2 D	2
279	11602	PARAMASIVAM	83	M	TVR	16/02/21	DM/SHTN/CKD	17-02-201	1D	3
280	11438	CITY BABU	72	M	TJ	16/02/21	DM/SHTN	17/02/21	2D	2
281	9881	FEROZ KHAN	71	M	TJ	09/02/21	CAD	21/02/21	3D	1
282	12795	MOHAMMED SIDDIQUE	56	M	TVR	21/02/21	DM	24/02/21	4D	1
283	12139	STELLA BRIDGT	57	F	TJ	18/02/21	SHTN DM	24/02/21	2D	2
284	17369	VUJAYARAMAN	65	M	TJ	10/03/21	T2DM	13/03/21	10D	1
285	15957	NALLAIYAN	62	M	TJ	05/03/21	SHTN, T2DM,CAD	13/03/21	3D	3
286	17853	ALAMELU	78	F	TJ	12\3\21	T2DM, SHTN	15\3\21	2D	2
287	18198	MARIYA JOHN	86	M	TJ	13\03\21	SHTN,CAD, COPD	19\03\21	4D	3

288	18307	KUZHANTHAITHAR ASU	64	F	TJ	14\03\21	SHTN	18\03\21	4D	1
289	20755	SRINIVASAN	80	M	TJ	23\03\21	SHTN	25\03\21	4D	1
290	21884	BAIRIYA	70	F	TJ	27/03/21	T2DM	27/03/21	2D	1
291	21694	KALYANASUNDARAM	75	M	TVR	26/03/21	T2DM	28/03/21	18D	1
292	22378	ANANTHI	48	F	TJ	29.03.21	T2DM, SCHIZOPHRENIA	01.04.21	1D	2
293	22475	HAMEED SULTHAN	83	M	TVR	30.03.21	T2DM/SHT	02.04.21	2D	2
294	24149	ARUMUGAM	75	M	TJ	04.04.21	SHT	05.04.21	5D	1
295	28607	SANNASI	75	M	TJ	31.03.21	T2DM	05.04.21	3D	1
296	24221	JAYAWARTHANARAJA	58	M	TJ	05.04.21	T2DM/SHT/CAHD	05.04.21	4D	3
297	23558	SUBRAMANIYAN	60	M	TJ	02.04.21	NIL	05.04.21	7D	Nil
298	24186	AMEER IBRAHIM	63	M	TJ	04.04.21	NIL	06.04.21	5D	Nil
299	24058	SURESH KUMAR	57	M	TJ	04.04.21	T2DM/SHT	07.04.21	3D	2
300	24652	NADANASABAPATHY	64	M	MAA	06.04.21	T2DM	07.04.21	5D	1
301	24186	AMEER IBRAHIM	63	M	TJ	04.04.21	NIL	06/04/21	2D	Nil
302	27956	RAGAVAN	65	M	TJ	16/04/21	T2DM/SHTN	16/04/21	4D	2
303	28199	DEVARAYAN	30	M	TJ	16/04/21	NIL	17/04/21	5D	Nil
304	27346	SIVANANTHAM	75	M	TJ	14/04/21	SHTN/T2DM/ACUTE ON CKD/OLD CVA	18/04/21	2D	4
305	28769	AMUTHA	46	F	TJ	19/04/21	T2DM/SHTN/CKD	19/04/21	1D	3
306	28633	MUTHUSAMY	70	M	TJ	18/04/21	SHTN/CKD	20/04/21	1D	2
307	Nil	RAVICHANDRAN	45	M	TJ	16/04/21	POST TRAUMATIC SEIZURE DISORDER WITH ACUTE ENCEPHALOPATHY	20/04/21	10D	2
308	28656	TAMILSELVI	55	F	TJ	20.04.21	NIL	20.04.21	2D	Nil
309	29647	SATHASIVAM	75	M	TJ	21/04/21	SHTN/CKD	21/04/21	2D	2
310	28656	VARADARAJAN	38	M	TJ	18.04.21	NIL	21.04.21	1D	Nil
311	28725	ANDIYAH	65	M	TJ	18.04.21	NIL	22.04.21	2D	Nil
312	29833	DURGASUNDARAM	75	M	TJ	21.04.21	SHTN/T2DM/CAD	24.04.21	1D	3
313	30759	RETHINASAMY LEO	57	M	TJ	24.04.21	NIL	24.04.21	4D	Nil
314	30488	SEKAR	53	M	TJ	23.04.21	CAD	25.04.21	2D	1
315	30435	SUMATHI	50	F	TJ	23.04.21	NIL	26.04.21	10D	Nil
316	31167	SRINIVASAN	81	M	TJ	26.04.21	SHTN/T2DM/CKD5/HCV +	26.04.21	4D	4
317	31392	KARTHIKEYAN	48	M	TJ	27.04.21	T2DM/CAD/OLD CVA/AKI	27.04.21	4D	4
318	31246	RAJESH	53	M	TJ	26.04.21	NIL	27.04.21	3D	Nil
319	31581	SUBRAMANIAN	67	M	PDU	27.04.21	NIL	27.04.21	5D	Nil
320	30749	ABDUL WAHAB	68	M	TJ	24.04.21	NIL	28.04.21	1D	Nil
321	31038	SRINIVASAN	68	M	TJ	25.04.21	T2DM/CKD/CAD/SHTN	29.04.21	2D	4

322	NIL	AHAMAD	45	M	Not known	25.04.21	NIL	29.04.21	2D	NIL
323	31392	KARTHIKEYAN	48	M	TJ	27.04.21	T2DM/CAD/AK/IQOLD CVA	27.04.21	7D	4
324	32108	SELVAN	52	M	TJ	29.04.21	CAD/T2DM/SHTN/	29.04.21	1D	3
325	31717	AHAMAD	17	M	TJ	27.04.21	RTA/HEAD INJURY/LEFT TEMPORAL ICH	29.04.21	2D	3
326	32478	MANIMALA	45	F	TJ	29.04.21	T2DM	30.04.21	3 D	1
327	31990	VISHNURAM	87	M	TJ	28.04.21	SHTN	01.05.21	1 D	1
328	31681	VENUGOPAL	65	M	TJ	27.04.21	T2DM/SHTN/CAD	1.05.21	1 D	3
329	32729	BALASUBRAMANIAM	64	M	TJ	30.04.21	SHTN	01.05.21	8 D	1
330	32480	KAMAR NISHA	48	F	NPM	29.04.21	SHTN/T2DM	02.05.21	5 D	2
331	32706	KAMALUDEEN	60	M	TJ	30.04.21	T2DM	02.05.21	3 D	1
332	33030	THILAGAM	66	F	TJ	01.05.21	SHTN	02.05.21	5 D	1
333	27414	CHINNATHAMBI	65	M	TJ	24.04.21	CAD/T2DM/SHTN/HYPOTHYROIDISM/P QST LEFT HERNIOPLASTY	2.05.21	5 D	5
334	33253	SELVARAJ	68	M	TVR	2.05.21	T2DM	3.05.21	1 D	1
335	32881	VELAMMAL	50	F	TJ	30.04.21	SHTN/T2DM	03.05.21	4 D	2
336	31653	KUPPARAO	77	M	TJ	27.04.21	SHTN	3.05.21	3 D	1
337	32839	GANAPATHI	78	M	TJ	30.04.21	NIL	03.05.21	1 D	NIL
338	33222	BALAKRISHNAN	72	M	TJ	2.05.21	T2DM	05.05.21	2 D	1
339	33204	RAMACHANDRAN	76	M	TJ	2.05.21	NIL	05.05.21	3 D	NIL
340	34297	DEEPA	35	F	TJ	05.05.21	T2DM	05.05.21	1 D	1
341	33411	AYEESHA BEEVI	55	F	TJ	03.05.21	SHTN/CAD	06.05.21	3 D	2
342	24971	SELVARAJ	58	M	TJ	07.04.21	T2DM/SHTN/CAD	06.05.21	5 D	3
343	32476	NATARAJAN	55	M	TJ	29.04.21	SHTN	06.05.21	4 D	1
344	34330	SENTHIL KUMAR	49	M	TJ	05.05.21	T2DM/SHTN	05.05.21	1 D	2
345	32599	DHARMAN	55	M	TJ	30.04.21	MYASTHENIA GRAVIS	05.05.21	6 D	1
346	33200	GOPALAKRISHNAN	66	M	TJ	02.05.21	SHTN/T2DM	06.05.21	2 D	2
347	33998	MANI	68	M	TJ	04.05.21	T2DM/CAD	06.05.21	3 D	2
348	33205	KUMAR RAO	54	M	TJ	02.05.21	T2DM/CAD	06.05.21	5 D	2
349	33053	PALANIAYYA	68	M	TJ	01.05.21	NIL	07.05.21	3 D	NIL
350	32979	JAGADESAN	72	M	TJ	01.05.21	NIL	06.05.21	7 D	NIL
351	NIL	GANESAN	83	M	TJ	06.05.21	NIL	08.05.21	7 D	NIL
352	33515	GIRIJA	55	F	TJ	03.05.21	T2DM/SHTN/CKD	07.05.21	2 D	3
353	34941	KALIYAPERUMAL	79	M	TJ	06.05.21	NIL	08.05.21	4 D	NIL
354	33070	HABIB ANSARI	65	M	TJ	01.05.21	T2DM,SHTN	07.05.21	2 D	2
355	34194	BASKAR	38	M	TJ	04.05.21	NIL	07.05.21	2 D	NIL
356	33363	ANNAMAYIL	75	F	TJ	03.05.21	T2DM	07.05.21	1 D	1
357	34532	INDHUJA	31	F	TJ	05.05.21	HYPOTHYROIDISM,MORBID OBESITY	08.05.21	4 D	2

358	34555	SELVARAJ	84	M	TJ	05.05.21	T2DM	08.05.21	5 D	1
359	35114	MALIK	68	M	TJ	07.05.21	CAD/SHTN	09.05.21	11 D	2
360	34607	MOHAMAD RAFIQ	43	M	TJ	06.05.21	NIL	09.05.21	01 D	Nil
361	32777	SELAM ADAIKAKALSAMY	65	M	TJ	30.04.21	PSYCHIATRIC DISORDER	09.05.21	5 D	1
362	33290	SENTHIL KUMAR	53	M	TJ	03.05.21	T2DM/SHTN/CAD	09.05.21	1 D	3
363	34552	CHITHRA	55	F	TJ	05.05.21	NIL	09.05.21	7 D	Nil
364	33624	SEKAR	69	M	TJ	03.05.20 1	T2DM	10.05.21	5 D	1
365	35653	SARAVANAN	54	M	TJ	05.05.21	T2DM	10.05.21	2 D	1
366	34221	ANBU	47	F	TJ	05.05.21	T2DM	09.05.21	3 D	1
367	32978	KARPUKARASI	58	F	TJ	01.05.21	T2DM	09.05.21	8 D	1
368	31730	SELVA MUTHUKUMAR	73	M	TJ	27.04.21	T2DM	10.05.21	3 D	1
369	34420	FARITHA BEGUM	46	F	TJ	05.05.21	T2DM	10.05.21	1 D	1
370	34478	VENKATESAN	49	M	TJ	05.05.21	T2DM	09.05.21	3 D	1
371	35809	SARBUNISHA	64	F	TJ	09.05.21	T2DM	10.05.21	2 D	1
372	34940	SARASWATHI	70	F	TJ	06.05.21	T2DM	10.05.21	5 D	1
373	35429	BALAMURUGAN	46	M	TJ	08.05.21	T2DM	08.05.21	2 D	1
374	35761	NEELAKANDAN	60	M	TJ	08.05.21	T2DM	09.05.21	7 D	1
375	35488	PALANIMUTHU	23	M	TJ	08.05.21	DUODENAL PREFORATION/POST LAPAROTOMY	09.05.21	3 D	2
376	36147	NAGARAJ	72	M	TJ	09.05.21	T2DM/HTN/CAD POST CABG	10.05.21	3 D	4
377	34569	NATARAJAN	85	M	TJ	06.05.21	T2DM	10.05.21	2 D	1
378	35130	MUTHURAMAN	75	M	TJ	07.05.21	T2DM	10.05.21	4 D	1
379	35477	KALYANI	63	F	TJ	08.05.21	T2DM	10.05.21	4 D	1
380	36582	LAKSHMI NARAYANAN	72	M	TJ	10.05.21	T2DM/SHTN	11.05.21	7 D	2
381	34477	BALAN	27	M	MV	05/05/21	T2DM/SHTN	09/05/21	3 D	2
382	33060	ARAIFA	73	F	TJ	01.05.21	T2DM/SHTN	10.05.21	3 D	2
383	36582	GUNABALASUNDARAM	62	M	TJ	10/05/21	T2DM/SHTN	11/05/21	5 D	2
384	35427	GOPAL	62	M	TJ	08.05.21	T2DM/SHTN	10.05.21	14 D	2
385	36451	KRISHNAMOORTHY	80	M	TJ	10.05.21		10.05.21	1 D	Nil
386	33663	ARUMUGAM	88	M	TJ	03.05.21		11/05/21	2 D	Nil
387	33028	PALANIVEL	77	M	TJ	05.05.21	T2DM / CAHD S/p CABG	10.05.21	6 D	2
388	35848	MANOHARAN	52	M	NMKL	09.05.21	SHTN/OLD CVA/ CKD 5	10.05.21	1 D	3
389	33663	ARUMUGAM	88	M	TJ	03.05.21	SHTN/CAD	11.05.21	10 D	2
390	35629	RAHMATH NISAH	61	F	TJ	08.05.21	NIL	12/05/21	3 D	Nil

391	33769	ISMATH BATCHA	67	M	TJ	04.05.21	NIL	11/05/21	7 D	Nil
392	36083	RANJITHAM	65	F	TJ	09/05/21	T2DM/SHTN	12.05.21	7 D	2
393	36489	KALYANAM	84	F	TJ	10.05.21	T2DM/SHTN	11/05/21	5 D	2
394	36036	CHINAIYAN	55	M	TJ	09.05.21	T2DM	12/05/21	2 D	1
395	34035	SAHAR BANU	64	F	TJ	04.05.21	SHTN/T2DM	11/05/21	3 D	2
396	35765	SASIKUMAR	44	M	TJ	08.05.21	T2DM	11/05/21	1 D	1
397	35436	SIVAGNANAM	80	M	TJ	08.05.21	SHTN	11/05/21	4 D	1
398	36469	ARUNACHALAM	80	M	TJ	10.05.21	T2DM/SHTN	12.05.21	3 D	2
399	36172	GURUMURTHI	51	M	TJ	09.05.21	NIL	12.05.21	5 D	Nil
400	36548	CHITHRA	58	F	KIK	10.05.21	SHTN/T2DM/CAD	13.05.21	10 D	3
401	35806	JAMES	56	M	TVR	08.05.21	FUNGAL SINUSITIS WITH RIGHT EYE CELLULITIS ?MUCORMYCOSIS	12.05.21	18 D	1
402	33028	PALANIVEL	77	M	TJ	01.05.21	CAD/BRONCHIAL ASTHMA	13.05.21	4 D	2
403	33722	AMEER JAHN BEGUM	55	F	TJ	04.05.21	NIL	13.05.21	2 D	Nil
404	36521	JANETH BEGUM	50	F	TJ	10.05.21	PLWHA/PTB/SHTN/T2DM	12.05.21	5 D	4
405	36897	MUTHU	84	M	TJ	11.05.21	SHTN/T2DM	12.05.21	2 D	2
406	37304	VICTOR WILLIAMS	74	M	TJ	13.05.21	NIL	14.05.21	2 D	Nil
407	37906	VENGATESAN	48	M	TJ	14.05.21	NIL	14.05.21	4 D	Nil
408	36472	VEDHAVALLI	63	F	TJ	10.05.21	T2DM	14.05.21	4 D	1
409	36267	VASANTHI	67	F	TJ	10.05.21	T2DM/SHTN	14.05.21	2 D	2
410	34392	VARIDHULAH KHAN	33	M	TJ	05.05.21	T2DM	14.05.21	3 D	1
411	38005	SUNDARAMBAL	76	F	TJ	14.05.21	CAD	14.05.21	5 D	1
412	37608	SUNDAR RAJ	52	M	TJ	13.05.21	SHTN	14.05.21	4 D	1
413	37003	RAJAM	79	F	TJ	12.05.21	T2DM	14.05.21	3 D	1
414	38006	LALITHA	71	F	TJ	14.05.21	T2DM	15.05.21	4 D	1
415	37793	DHANASEKAR	45	M	TJ	14.05.21	SHTN /T2DM/CKD	14.05.21	4 D	3
416	37208	ANANDHA KUMAR	51	M	TJ	12.05.21	T2DM/SHTN	14.05.21	10 D	2
417	37611	MANGAIYARKARASI	67	F	TJ	13.05.21	T2DM	15.05.21	2 D	1
418	34944	VARADHARAJAN	74	M	TJ	06.05.21	T2DM	16.5.21	5 D	1
419	36146	THIRUVENGADAM	52	M	TJ	12.5.21	T2DM	15.05.21	4 D	1
420	37539	NAGARAJAN	68	M	TJ	13.05.21	T2DM / SHTN	15.05.21	1 D	2
421	38458	RAJ KUMAR	39	M	TJ	15.05.21	T2DM	15.05.21	7 D	1
422	34937	JAYAMANI	65	F	TJ	6.05.21	NIL	15.05.21	2 D	Nil
423	36419	KALA RANI	63	F	TJ	10.5.21	T2DM	15.5.21	7 D	1
424	37961	MANIMEGALAI	60	F	TJ	14.5.21	NIL	15.05.21	2 D	Nil
425	33705	MURALIDHARAN	65	M	TJ	3.5.21	T2DM	15.05.21	3 D	1
426	36875	VUAYA LAKSHMI	52	F	TJ	11.05.21	T2DM	15.05.21	8 D	1
427	36326	IBRAHIM	53	M	TJ	10.5.21	BRANCHIAL ASTHMA	16.05.21	4 D	1

428	38067	CHANDRABOSE	70	M	TJ	14.5.21	T2DM	16.5.21	4 D	1
429	35638	MEENA	70	F	TJ	8.5.21	T2DM	15.05.21	8 D	1
430	37546	PANNER SELVAM	64	M	NPM	13.05.21	STHN /T2DM	16.5.21	4 D	2
431	37782	PARVATHY	46	F	PDY	14.05.21	T2DM	16.5.21	7 D	1
432	38343	KALAI VANI	19	F	TJ	15.05.21	NIL	16.05.21	6 D	Nil
433	36981	JOHN BRITTO	56	M	TJ	11.5.21	SHTN /T2DEM / CAD	15.05.21	7 D	3
434	36353	DHANA SEKAR	45	M	TJ	10.05.21	HYPOTHYROIDISM, NON HODGKIN'S LYMPHOMA	15.05.21	3 D	2
435	36224	KARUNANITHI	63	M	TJ	10.05.21	COPD/ CVA	16.05.21	3 D	2
436	38111	ADAIKJALAM	55	M	TJ	14.05.21	SHTN / HYPOTHYROIDIAM / POST RENAL TRANSPLANT	16.05.21	3 D	3
437	37670	THANGARAJ	82	M	TJ	13.05.21	T2DM/ SHTN/CAD	15.05.21	5 D	3
438	37072	VASANTHA	65	F	TJ	12.05.21	NIL	16.05.21	12 D	Nil
439	36690	GUNASEKARAN	65	M	TJ	11.05.21	NIL	16.05.21	6 D	Nil
440	35245	SASI KUMAR	40	M	TJ	07.05.21	NIL	16.05.21	4D	Nil
441	38497	MATHIALAGAN	52	M	TJ	15.05.21	SHTN	16.05.21	7 D	1
442	38138	PANDIDURAI	60	M	TJ	14.05.21	T2DM / SHTN	17.05.21	10 D	2
443	35805	SYED KADAR BATCHA	65	M	TJ	8.5.21	NIL	17.05.21	3 D	Nil
444	37127	USHA	55	F	TJ	12.05.21	SHTN /T2DM	16.5.21	3 D	2
445	37557	KOWSALYA	56	F	TJ	13.05.21	NIL	17.05.21	1 D	Nil
446	38312	PANNER SELVAM	73	M	TJ	15.05.21	T2DM	17.05.21	3 D	1
447	33639	ANBALAGAN	69	M	TJ	03.5.21	T2DM / CAD/ACS/ STEMI	16.05.21	1 D	4
448	37242	ARPUTHA SAMYO	90	M	TJ	12.5.21	CKD/ CAD/ SHTN	16.05.21	3 D	3
449	36931	RAMADOSS	77	M	TJ	11.05.21	BPH / CKD	16.05.21	2 D	2
450	35341	MUTHUEZHILAN	59	M	TJ	7.05.21	SHTN / CKD / POST RENAL TRANSPLANT	16.5.21	5 D	3
451	38357	RAJARETHINAM	67	M	TJ	15.05.21	NO	16.5.21	3 D	Nil
452	37201	VALLI	72	F	TJ	12.5.21	T2DM / CAD/ACS/ STEMI	16.5.21	1 D	4
453	36431	GANESAN	43	M	TJ	13.5.21	T2DM / LEFT LL DVT	16.5.21	1 D	2
454	37553	KASTHURI	60	F	TJ	13.05.21	SHTN / T2DM	17.5.21	3 D	2
455	38692	KASTHURINATHAN	69	M	TJ	16.5.21	NIL	17.5.21	2 D	Nil
456	36679	NADIAMMAL	70	F	TJ	11.5.21	NIL	17.5.21	3 D	Nil
457	38101	TAMIL SELVI	68	F	TJ	14.05.21	NIL	17.5.21	4 D	Nil
458	39070	BALASUBRAMANIAN	75	M	TPJ	17.5.21	SHTN / T2DM / CKD /CAD	17.5.21	4 D	4
459	38078	ARUMUGAM	62	M	PER	14.05.21	T2DM	17.5.21	2 D	1
460	36934	SELVA LAKSHMI	71	F	TJ	11.5.21	SHTN / T2DM / CAD	17.5.21	3 D	3
461	38317	MANI KUMAR	70	M	TJ	15.5.21	T2DM / STHN /CKD. ON HD	17.5.21	4 D	3

462	36611	SURIYA MOORTHY	73	M	TJ	11.05.21	NIL	17.05.21	3 D	Nil
463	38931	MAHA LINGAM	68	M	MV	17.5.21	SHTN / T2DM / COPD CAD	17.05.21	10 D	4
464	31880	SHANMUGA VEL	58	M	TJ	11.05.21	T2DM / CKD	18.5.21	1 D	2
465	37607	SRIDHAR JAYA BALAN	59	M	TPJ	13.5.21	SHTN / CAD / POST. INFARCTION FAILURE	17.5.21	7 D	3
466	37744	GOVINDARAJ	73	M	KMU	13.05.21	T2DM/HYPERGLYCEMIC STATE/METABOLIC ENCELOPATHY	18.05.21	2 D	3
467	31667	AJITH KUMAR	23	M	TJ	27.04.21	RESPIRATORY FAILURE	18.05.21	4 D	1
468	38082	SRINIVASA RAGAVAN	56	M	TJ	14.05.21	SHTN/T2DM/CKD5	18.05.21	2 D	3
469	35541	KAJAMAITHEEN	52	M	TJ	08.05.21	T2DM	18.05.21	2 D	1
470	38443	CHANDRA MOULI	77	M	TVR	15.05.21	SHTN/CAD	19.05.21	4 D	2
471	38607	JAYARAMAN	65	M	TJ	16.05.21	T2DM/SHTN/CAD	18.05.21	2 D	3
472	37736	SENTHIL KUMAR	53	M	TJ	13.05.21	T2DM	18.05.21	2 D	1
473	38610	UMAPATHY	64	M	TJ	16.05.21	RESPIRATORY FAILURE	18.05.21	5 D	1
474	38779	PURUSHOTHAMAN	67	M	ED	16.05.21	RESPIRATORY FAILURE	19.05.21	13 D	1
475	38839	CHAKRAPAANI	63	M	TJ	15.05.21	SHTN	18.05.21	2 D	1
476	38580	KRISHNAMOORTHY	81	M	TJ	16.05.21	T2DM	19.05.21	9 D	1
477	37415	NADIMUTHU	64	M	CUPI	13.05.21	T2DM/SHTN	18.05.21	4 D	2
478	39062	VAIYAPURI	54	M	TJ	18.05.21	RESPIRATORY FAILURE	19.05.21	5 D	1
479	35830	MAHARAJAN	61	M	TJ	09.05.21	T2DM	19.05.21	6 D	1
480	38613	REETHA	65	F	TVR	16.05.21	T2DM/SHTN	19.05.21	4 D	2
481	38427	SHANMUGAM	78	M	TJ	15.05.21	SHTN/T2DM	20.05.21	2 D	2
482	38281	MOHANDAS	65	M	TJ	15.05.21	T2DM	20.05.21	5 D	1
483	37637	SAMIYAPPAN	45	M	TJ	13.05.21	SHTN	20.05.21	4 D	1
484	39555	SOMASUNDARAM	64	M	TJ	18.05.21	T2DM/SHT	20.05.21	2 D	2
485	38425	NISHA	57	F	TJ	15.05.21	T2DM/SHT	19.05.21	2 D	2
486	38148	RAMACHANDRAN	69	M	TJ	14.05.21	T2DM	19.05.21	2 D	1
487	38178	MEENA	25	F	TVR	15.05.21	NIL	19.05.21	5 D	Nil
488	38461	IMAAAN ALI	54	M	TJ	15.05.21	SHTN	19.05.21	10 D	1
489	38470	ANNADURAI	57	M	TJ	15.05.21	SHTN/SEVER MR	19.05.21	1 D	2
490	39155	BALAKRISHNAN	64	M	TJ	17.05.21	T2DM/SHTN/CAD	19.05.21	4 D	3
491	39153	DANADHAN	68	M	TJ	17.05.21	T2DM/SHTN/CAD	19.05.21	1 D	3
492	Nil	GOVINDHARAJ	67	M	TJ	17.05.21	NIL	19.05.21	3 D	Nil
493	38137	MURUGAN	34	M	TJ	14.05.21	CAHD/CKD ON HD	19.05.21	3 D	2
494	39431	NANDHA	55	M	TJ	18.05.21	T2DM/LEFT DIABETIC FOOT/SEPSIS	19.05.21	2 D	3
495	36831	PRAKASAM	67	M	TJ	11.05.21	T2DM/SHTN	19.05.21	1 D	2
496	38932	RUKMANI	73	F	TJ	17.05.21	T2DM/HSHTN/CAD/METABOLIC ENCETHANOPATHN	19.05.21	2 D	4

497		SHANMUGAVEL	56	M	TJ	17.05.21	NIL	19.05.21	10 D	Nil
498	38010	THIRUNEELGANDAN	63	M	TJ	14.05.21	T2DM/SHTN/CKD	20.05.21	2 D	3
499	68113	USHARANI	55	F	TJ	15.05.21	T2DM/HYPEROSMOLAR NON KETOTIC STATE/LEFT DIABETIC FOOT/ANEMIA	19.05.21	3 D	4
500	39987	VENKATESAN	62	M	TJ	20.05.21	T2DM/DKA	20.05.21	5 D	2
501	40366	JAYAKUMAR	60	M	TJ	21.05.21	SHTN	21.05.21	1 D	1
502	40209	MURUGANANDHAM	51	M	TJ	20.05.21	CA OROPHARYNX	20.05.21	1 D	1
503	38650	NIZAM	54	M	TJ	20.05.21	NIL	20.05.21	5 D	Nil
504	40207	REVATHI	32	F		20.05.21	NIL	20.05.21	2 D	Nil
505	39928	RAMASAMY	56	M	TJ	20.05.21	NIL	20.05.21	2 D	Nil
506	38546	SAMSUDEEN	67	M	TJ	16.05.21	T2DM/SHTN/CAD/PARKINSONS DISEASE/INCIDENTAL COVID POSITIVE	20.05.21	2 D	3
507	35819	SUNDHAR RAJ	54	M	TJ	09.05.21	T2DM/SHTN/CAD	21.05.21	2 D	3
508	38482	KALYANASUNDARAM	59	M	TVR	15.05.21	SHTN	21.05.21	8D	1
509	40193	SARITHA	31	F	TJ	20.05.21	NIL	21.05.21	2D	Nil
510	40212	ASHOK KUMAR	54	M	TJ	20.05.21	SHTN	21.05.21	2D	1
511	39452	CHITHRA	54	F	TJ	18.05.21	T2DM	21.05.21	10 D	1
512	40169	JAYANTHI	48	F	TJ	20.05.21	NIL	22.05.21	20 D	Nil
513	37768	GOVINDHARAJAN	65	M	TJ	14.05.21	NIL	21.05.21	1 D	Nil
514	37700	SUNDARAMOORTHY	54	M	TJ	13.05.21	HYPERTENSIVE	22.05.21	3 D	1
515	38456	KAMALA	63	F	TJ	15.05.21	T2DM/SHTN/CAD	22.05.20021	1 D	3
516	38956	VENKATRSMAN	90	M	TJ	17.05.21	NIL	21.05.21	3 D	Nil
517	38796	JEYAKODI	53	M	TJ	16.05.21	T2DM	22.05.21	4 D	1
518	39779	DURAI SATTANATHAN	48	M		16.05.21	NIL	16.05.21	2 D	Nil
519	39746	DRAIRAJ	60	M		16.05.21	NIL	16.05.21	3 D	Nil
520	37229	SUBRAMANIYAM	55	M	TJ	12.05.21	T2DM	21.05.21	6 D	1
521	39077	ANANDH	45	M	TJ	17.05.21	T2DM	21.05.21	9 D	1
522	39560	JEYALAKSHMI	50	F	TJ	18.05.21	T2DM/SHTN	23.05.21	4 D	2
523	39423	MATHIVANAN	65	M	TJ	18.05.21	NIL	22.05.21	2 D	Nil
524	36111	ARUMUGAM	75	M	NPM	12.05.21	T2DM/SHTN	23.05.21	7 D	2
525	37500	RAMAMOORTHY	60	M	TVR	13.05.21	T2DM	23.05.21	6 D	2
526	38505	VIMALA	57	F	TJ	15.05.21	NIL	22.05.21	3 D	Nil
527	393111	KANGARAJ	54	M	TJ	18.05.21	SHTN/CKD/UTI/SIGMOID VOLVULUS	22.05.21	2 D	4

528	37302	SOMASUNDARAM	69	M	TJ	13.05.21	CAD/SHTN	22.05.21	5 D	2
529	35616	VIJAYRAGAVAN	78	M	TJ	08.05.21	T2DM	23.05.21	9 D	1
530	39813	KARUNANITHI	72	M	TJ	19.05.21	T2DM/SHTN/CAD	22.05.21	3 D	3
531	36195	ANTHONISAMY	53	M	TJ	10.05.21	T2DM/SHTN	22.05.21	2 D	2
532	37991	BALAMURUGAN	30	M	TVR	14.05.21	NIL	22.05.21	4 D	NII
533	37666	MANIVASAGAM	56	M	TJ	13.05.21	T2DM/SHTN	22.05.21	3 D	2
534	38439	JAMAL MOHAMED	55	M	TVR	15.05.21	T2DM/SHTN	22.05.21	3 D	2
535	39063	KANIMANI	67	F	TJ	17.05.21	T2DM/SHTN	23.05.21	2 D	2
536	37759	ROBERT	27	M	TJ	14.05.21	NIL	22.05.21	6 D	NII
537	39038	JOTHIAMMAL	65	F	TJ	17.05.21	SHTN	22.05.21	6 D	1
538	39916	GANESAN	86	M	TJ	19.05.21	T2DM	24.05.21	2 D	1
665	43462	THAYALNAYAGI	64	F	TJ	29.05.21	NIL	29.05.21	4 D	NII
539	39941	CHNDRA	25	F	TJ	19.05.21	NIL	23.05.21	1 D	NII
540	39364	SRINIVASAN	45	M	TJ	18.05.21	T2DM	24.05.21	2 D	1
541	40106	KALIYAMMAL	70	F	TJ	20.05.21	NIL	23.05.21	2 D	NII
542	37241	EDWIN INBARAJ	50	M	TJ	12.05.21	T2DM	23.05.21	3 D	1
543	39166	ANAND	46	M	TJ	17.05.21	SHTN/CKD 5 ON HD	24.05.21	16 D	2
544	39191	VUJAYA	48	F	TJ	18.05.21	SHTN/T2DM	23.05.21	3 D	2
545	40290	VENKATAMMAL	65	F	TJ	20.05.21	T2DM	23.05.21	2 D	1
546	39688	VALLI	45	F	TJ	19.05.21	NIL	23.05.21	3 D	NII
547	NII	SENTHAMILSELVI	61	F	TJ	22.05.21	SHTN	23.05.21	4 D	1
548		PERUMAL	61	M	TJ	22.05.21	T2DM	23.05.21	4 D	1
549	NII	KUMAR	52	M	TJ	08.05.21	T2DM/SHTN/CKD	23.05.21	4 D	3
550	NII	LAKSHMI	67	F	TJ	22.05.21	T2DM/SHTN	23.05.21	3 D S	2
551	NII	KATHIRAVAN	53	M	TJ	18.05.21	SHTN	23.05.21	03 D	1
552	36515	GURUSAMY	71	M	TJ	10.05.21	NIL	23.05.21	7 D	NII
553	38471	LATHA	45	F	TJ	15.05.21	NIL	24.05.21	1 D	NII
554	39583	FRANCIS	80	M	TJ	19.05.21	SHTN/T2DM/CVA LEFT HEMIPAREISIS	22.05.21	2 D	3
555	39029	BOOPATHY	54	M	TJ	17.05.21	T2DM	23.05.21	5 D	1
556	37722	BASKARAN	50	M	TJ	13.05.21	T2DM	23.05.21	1 D	1
557	40439	GILBERT VICTOR	78	M	TJ	21.05.21	SHTN / T2DM / CAD	23.05.21	1 D	3
558	36515	THOULAD BEGUM	50	F	TJ	11.05.21	T2DM / SHTN	23.05.21	2 D	2
559	34669	MURUGESAN	56	M	TJ	06.05.21	T2DM	24.05.21	2 D	1
560	40908	SUBRAMANIAN	54	M	TJ	22.05.21	T2DM	25.05.21	7 D	1
561	39502	MOHON	55	M	TJ	18.05.21	T2DM/METABOLIC ENCEPHALOPATHY	24.05.21	10 D	2
562	39540	BASKARAN	59	M	TJ	18.05.21	ALCOHOLIC LIVER DISEASE/DECOMPENSATED LIVE DISEASE	25.05.21	1 D	2
563	41126	INDHRANI	72	F	TJ	23.05.21	T2DM/SHTN	24.05.21	1 D	2

564	40860	SHANMUGASUNDA RAM	57	M	TJ	22.05.21	T2DM/CVA	24.05.21	7 D	2
565	40298	JOSEPH VINCENT RAJ	79	M	TJ	20.05.21	SHTN/CVA	25.05.21	2 D	2
566	40908	SUBRAMANIAN	54	M	TJ	22.05.21	T2DM	25.05.21	1 D	1
567	40386	RUKMANI	65	F	TJ	21.05.21	T2DM	25.05.21	5 D	1
568	40946	DHAMODHARAN	76	M	TJ	22.05.21	T2DM	24.05.21	5 D	1
569	39382	THANGARAJ	83	M	TJ	18.05.21	SHTN	24.05.21	3 D	1
570	40183	ARIFA BEGAM	46	F	TJ	20.05.21	SHTN	24.05.21	7 D	1
571	40584	KATHIRAVAN	74	M	TJ	21.05.21	NIL	24.05.21	5 D	Nil
572	39073	GOWTHAM	29	M	TJ	17.05.21	NIL	24.05.21	4 D	Nil
573	40283	ABDUL MUTHALIF	67	M	TVR	20.05.21	T2DM/SHTN	24.05.21	3 D	2
574	39156	GUNASEKARAN	37	M	TVR	17.05.21	NIL	24.05.21	2 D	Nil
575	38334	BANUMATHI	75	F	TJ	15.05.21	SHTN	24.05.21	1 D	1
576	40184	KANNAIYAN	72	M	TVR	20.05.21	SHTN/CAD	25.05.21	6 D	2
577	39937	UDATHULLAH	64	M	TJ	19.05.21	NIL	24.05.21	3 D	Nil
578	41023	BANUMATHI	60	F	TJ	22.05.21	DM/CVA RIGHT HEMIPARETIS	25.05.21	1 D	2
579	40272	CHITHRA	58	F	TJ	20.05.21	SHTN/T2DM	25.05.21	7 D	2
580	41877	GANESAN	65	M	TJ	25.05.21	T2DM	25.05.21	4 D	1
581	40968	JABARULLA	64	F	TJ	22.05.21	T2DM/SHTN	26.05.21	4 D	2
582	41060	LAKSHMI GANDHI	37	F	TJ	22.05.21	NIL	26.05.21	3 D	Nil
583	40450	MAHALINGAM	80	M	TJ	21.05.21	SHTN/T2DM/CKD	25.05.21	3 D	3
584	39929	MAHESHWARI	25	F	TJ	19.05.21	NIL	25.05.21	2 D	Nil
585	40920	MALAR KODI	61	F	TJ	22.05.21	SHTN/CAD/HYPOTHYROIDISM	25.05.21	6 D	3
586	40749	MATHIAZHAGA N	61	M	TJ	22.05.21	NIL	26.05.21	7 D	Nil
587	41744	MEHARBAN BEEVI	71	F	TJ	24.05.21	SHTN/T2DM	25.05.21	2D	2
588	40609	PAKKIRISAMY	50	M	TJ	21.05.21	SHTN/T2DM/HYPOTHYROIDISM	25.05.21	7 D	3
589	35794	RADHA	44	F	TJ	08.05.21	T2DM	25.05.21	2 D	1
590	42423	RAMAMOORTHIY	54	M	TJ	24.05.21	NIL	25.05.21	4 D	Nil
591	39478	SELVAM	60	M	TJ	18.05.21	SHTN/T2DM	25.05.21	6 D	2
592	41072	SHANMUGANAT HAN	62	M	TJ	22.05.21	NIL	25.05.21	5 D	Nil
593	39426	SHANMUGAM	53	M	TJ	18.05.21	NIL	25.05.21	10 D	Nil
594	38170	RAJENDIRAN	60	M	TJ	15.05.21	T2DM/SHTN	25.05.21	1 D	2
595	41229	KRISHNAMMAL	63	F	TJ	23.05.21	T2DM	25.05.21	2 D	1
596	40561	CHINNAKANNU	65	M	TJ	21.05.21	T2DM/ NECROTIZING FASCITIS	25.05.21	3 D	2

597	40119	KARTHIKEYAN	42	M	TJ	20.05.21	NIL	25.05.21	7 D	NII
598	39898	RAJIV GANDHI	36	M	TJ	19.05.21	NIL	25.05.21	15 D	NII
599	40866	ANBUMALAR	52	F	TVR	22.05.21	SHTN/T2DM	25.05.21	15 D	2
600	39573	SELVARAJ	46	M	KRR	19.05.21	T2DM	25.05.21	7 D	1
601	40267	ALAGAR	60	M	TJ	20.05.21	T2DM	26.05.21	4 D	1
602	41584	KARUPAIYAN	80	M	TJ	24.05.21	CAD	27.05.21	4 D	1
603	40241	EGAMBARAM	55	M	TJ	20.05.21	CKD/T2DM	26.05.21	2 D	2
604	41396	FAJARBEEVI	64	F	TJ	23.05.21	T2DM/SHTN	27.05.21	4 D	2
605	41435	GOVINDHAN	70	M	TJ	24.05.21	T2DM/SHTN/CAD/POST CABG	26.05.21	3 D	4
606	41629	KASINATHAN	50	M	TJ	24.05.21	NIL	27.05.21	2D	NII
607	39989	MOHAMAD FAROOQ	60	M	TJ	20.05.21	T2DM/SHTN	26.05.21	5 D	2
608	40979	NAGARATHINAM	65	F	TJ	22.05.21	T2DM	26.05.21	12 D	1
609	39545	RAJENDRAN	63	M	AYR	18.05.21	CKD/T2DM/SHTN	26.05.21	11 D	3
610	37778	RAMASAMY	72	M	TJ	14.05.21	NIL	26.05.21	4 D	NII
611	38440	SATHYASEELAN	28	M	AYR	15.05.21	RTA/BLUNT TRAUMA ABDOMEN/GASTRIC PERFORATION OMENTAL PATCH REPAIR/POST SPLENECTOMY STATUS/FECAL FISTULA	26.05.21	6 D	4
612	36551	SENTHIL KUMAR	48	M	TJ	10.05.21	NIL	26.05.21	5 D	NII
613	41685	SIVANANTHAM	45	M	TJ	19.05.21	NIL	27.05.21	2 D	NII
614	41982	UMA RASINA	61	F	TJ	25.05.21	SHTN	26.05.21	6 D	1
615	41685	VENKATRAMAN	86	M	TJ	24.05.21	NIL	26.05.21	6 D	NII
616	41773	IRAKAPERUMMAL	80	M	TJ	24.05.21	T2DM	27.05.21	6 D	1
617	39874	BALASUBRAMANIAN	66	M	TJ	19.05.21	T2DM/SHTN	28.05.21	1 D	2
618	41343	THANAGARASU	58	M	TJ	23.05.21	T2DM/SHTN/CKD/ANEMIA	27.05.21	4 D	4
619	39479	AMSU	80	M	TVR	18.05.21	NIL	27.05.21	4 D	NII
620	49480	BALAIYAN	64	M	TJ	21.05.21	CAD/BROMCHIAL ASTHMA/LEFT CSOM	27.05.21	2 D	3
621	42846	RAGAHAVAN K	72	M	TJ	27.05.21	T2DM	27.05.21	6 D	1
622	39986	AMEENUDEEN	61	M	TJ	20.05.21	T2DMSHTYN/CKD	28.05.21	4 D	3
623	38561	SATYA NARAYANAN	68	M	TJ	17.05.21	T2DM/SHTN	28.05.21	2 D	2
624	41171	PANCHACHARAN	64	M	AYR	23.05.21	T2DM/CKD	27.05.21	2 D	2
625	42152	RANI	42	F	TJ	25.05.21	SHTN	28.05.21	3 D	1
626	37294	ARUNACHALAM	47	M	TJ	12.05.21	T2DM	27.05.21	4 D	1
627	42168	MATHIVANAN	68	M	TJ	25.05.21	T2DM/SHTN	28.05.21	4 D	2
628	41624	SELVA MANI	60	M	TJ	24.05.21	T2DM	27.05.21	2 D	1
629	40417	ABDUL JABBAR	66	M	TJ	21.05.21	SHTN	27.05.21	4 D	1
630	41291	SURESH	37	M	TJ	23.05.21	NIL	27.05.21	4 D	NII

631	38530	AANDAL	41	F	TJ	16.05.21	NIL	28.05.21	6 D	Nil
632	39040	MOHAN	60	M	TJ	17.05.21	NIL	27.05.21	4 D	Nil
633	42105	SHABUR JOHN	56	F	TJ	25.05.21	NIL	28.05.21	3 D	Nil
634	41778	YAMARSINGH	65	M	TJ	24.05.21	T2DM	27.05.21	4 D	1
635	41393	SEEMAN	70	M	TJ	23.05.21	NIL	27.05.21	14 D	Nil
636	42803	RAMAN	52	M	TJ	27.05.21	NIL	28.05.21	3 D	Nil
637	41820	ANANDHAVALLI	58	F	TJ	25.05.21	SHTN	26.05.21	2 D	1
638	42797	ARUMAIKANNU	72	M	TJ	27.05.21	NIL	27.05.21	1 D	Nil
639	40206	AMSAM	80	F	TJ	20.05.21	NIL	28.05.21	7 D	Nil
640	40342	MANIMEGALAI	45	F	TJ	21.05.21	NIL	29.05.21	7 D	Nil
641	42590	MANGEYARKARASI	55	F	TJ	27.05.21	NIL	29.05.21	4 D	Nil
642	42156	MAHALAKSHMI	59	F	TJ	25.05.21	T2DM	29.05.21	4 D	1
643	40945	SUNDARAJAN	65	M	TJ	22.05.21	NIL	28.05.21	2 D	Nil
644	40206	AMSAM	80	F	TJ	20.05.21	NIL	28.05.21	2 D	Nil
645	41390	MAHALINGAM	65	M	TVR	23.05.21	NIL	28.05.21	4 D	Nil
646	40512	KALAIYAMOORTHY	70	M	TJ	21.05.21	T2DM	29.05.21	3 D	1
647	42218	UMARANI	66	F	TJ	26.05.21	T2DM	28.05.21	3 D	1
648	39892	FATHAMUTHU	50	F	TJ	19.05.21	T2DM/SHTN	28.05.21	5 D	2
649	40443	CHELLAIYAN	80	M	TJ	21.05.21	T2DM	29.05.21	16 D	1
650	38548	MANIKANDAN	29	M	TJ	16.05.21	NIL	28.05.21	3 D	Nil
651	42264	JAGANATHAN	59	M	TJ	26.05.21	T2DM/SHTN	29.05.21	8 D	2
652	37727	VASANTHA	62	F	TJ	13.05.21	SHTN/HYPOTHYROID	29.05.21	7 D	2
653	41433	GANGA	68	F	TJ	24.05.21	T2DM/SHTN/HYPOTHYROIDSM	28.05.21	6 D	3
654	31103	KARUPPAIYAN	61	M	TJ	17.05.21	T2DM/SHTN/CKD 5	28.05.21	9 D	3
655	74488	RAVIKUMAR	47	M	TJ	26.05.21	T2DM/SHTN	29.05.21	8 D	2
656	36442	CHANDRAN	56	M	TJ	10.05.21	CAD/POST INFRACTION FAILURE	30.05.21	8 D	2
657	42914	VENKATACHALAM	49	M	TJ	27.05.21	SHTN	29.05.21	5 D	1
658	42860	RAJU	65	M	TJ	27.05.21	T2DM/SHTN	30.05.21	6 D	2
659	42894	KARUPPAIYAN	80	M	TJ	27.05.21	SHTN/T2DM/CAD	29.05.21	7 D	3
660	42218	UMARANI	66	F	TJ	26.05.21	T2DM	28.05.21	11 D	1
661	39946	RAJESH	60	M	TJ	19.05.21	T2DM/SHTN	25.05.21	4 D	2
662	42190	DHAKSHINAMOORTHY	72	M	TJ	26.05.21	T2DM/SHTN/CKD	30.05.21	18 D	3
663	42911	PAKKIRISAMY	73	M	TJ	27.05.21	T2DM/SHTN/CAD/POST CABG	30.05.21	7 D	4
664	39792	RANI	45	F	TJ	19.05.21	NIL	29.05.21	2 D	Nil
666	43607	VADIVEL	47	M	TJ	30.05.21	T2DM	30.05.21	6 D	1
667	41501	KALIYAPERUMAL	70	M	TJ	24.05.21	NIL	29.05.21	9 D	Nil
668	38874	UMA DEVI	62	F	TJ	17.05.21	T2DM/SHTN	29.05.21	2 D	2
669	43108	RAJALAKSHMI	70	F	TJ	28.05.21	T2DM	30.05.21	4 D	1

670	43769	JOYCEMARY	47	F	TJ	30.05.21	HYPERTHYROIDISM	30.05.21	4 D	1
671	42965	NEELAVATHI	60	F	TJ	28.05.21	T2DM/CAD	30.05.21	2 D	2
672	41128	MATHIALAGAN	55	M	TJ	23.05.21	T2DM/DIABETIC NEPHROPATHY/CKD	30.05.21	16 D	3
673	41216	DHARMARAJ	62	M	TJ	23.05.21	T2DM	30.05.21	4 D	1
674	40739	BATHURNISHA	60	F	TJ	21.05.21	T2DM/SHTN/PSYCHIATRIC DISORDER	30.05.21	5 D	3
675	40274	GOVIDAMMAL	80	F	TJ	29.05.21	SEIZURE DISORDER	30.05.21	2 D	1
676	39480	CHINNAPILLAI	67	M	TJ	18.05.21	T2DM/SHTN	30.05.21	2 D	2
677	43894	SHANMUGAM	80	M	TJ	31.05.21	T2DM/SHTN	31.05.21	2 D	2
678	43567	VASANTHA	58	F	TJ	29.05.21	T2DM/SHTN	31.05.21	6 D	2
679	3838	RENUKA	46	F	TJ	15.05.21	T2DM/SHTN	30.05.21	5 D	2
680	42354	SIVANANTHAM	55	M	TJ	26.05.21	SHTN	30.05.21	5 D	1
681	41168	SARASWATHI	60	F	TJ	23.05.21	NIL	30.05.21	2 D	Nil
682	43620	JAWAHAR	40	M	TJ	30.05.21	NIL	31.05.21	3 D	Nil
683	39476	KANNAGI	36	F	TJ	18.05.21	HYPOTHYROIDISM	31.05.21	6 D	1
684	42055	RAGHAVENDRA RAO	90	M	TJ	25.05.21	SHTN/T2DM/CAD	31.05.21	3 D	3
685	41275	RAHAMATHKANI	65	F	TJ	23.05.21	T2DM/SHTN/CKD	31.05.21	1 D	3
686	44219	SHAHUL HAMEED	53	M	TJ	31.05.21	T2DM/CAD	01.06.21	2 D	2
687	44007	MANIMEGALAI	67	F	TJ	31.05.21	SHTN	31.05.21	3 D	1
688	43270	GANESAN	86	M	TJ	29.05.21	NIL	31.05.21	2 D	Nil
689	40385	KUMAR	47	M	TJ	21.05.21	COPD/COR PULMONALE	01.06.21	2 D	2
690	43408	TAMIL SELVI	60	F	TJ	29.05.21	T2DM	31.05.21	3 D	1
691	41627	KARUPPIAH	72	M	TJ	27.05.21	NIL	31.05.21	3 D	Nil
692	43220	GOWRI	45	F	TJ	28.05.21	NIL	01.06.21	3 D	Nil
693	39755	ILAKUVAN	67	M	TJ	19.05.21	SHTN/CAD	31.05.21	12 D	2
694	41512	RAHMATH NISHA	66	F	TJ	30.05.21	NIL	31.05.21	1 D	Nil
695	43882	SHAJAHAN	64	M	TJ	31.05.21	SHTN	01.06.21	4 D	1
696	42472	RAJAMMAL	80	F	TJ	26.05.21	SHTN/T2DM	31.05.21	6 D	2
697	42867	RAJENDRAN	71	M	TJ	27.05.21	T2DM	31.05.21	7 D	1
698	41821	NAGARAJAN	75	M	TJ	28.05.21	SHTN	01.06.21	7 D	1
699	43082	CHINNAPPA	51	M	TVR	22.05.21	T2DM/SHTN/POSTRENAL TRANSPLANT	01.06.21	7 D	3
700	40742	SALATHMARY MARTIN	56	F	TJ	21.05.21	T2DM	01.06.21	5 D	1
701	43731	VASIR AHAMED	29	M	TJ	30.05.21	NIL	01.06.21	5 D	Nil
702	43761	ABDUL AJEESH	76	M	TJ	30.05.21	CVA/ LEFT HEMIPLEGIA	01.06.21	6 D	2
703	43554	BABY SAROJA	67	F	TJ	29.05.21	NIL	01.06.21	3 D	Nil
704	43548	MALARKODI	60	F	TJ	29.05.21	T2DM/SHTN/HYPOTHYROIDISM	02.06.21	3 D	3
705	41765	MUTHAIYAN	70	M	TJ	29.05.21	T2DM/SHTN	01.06.201	3 D	2
706	42431	SELVARAJ	66	M	TVR	25.05.21	SHTN/CAD/CKD	01.06.21	5 D	3

707	43621	UMA	58	F	TJ	30.05.21	NIL	01.06.21	3 D	Nil
708	44227	ALAGESAN	60	M	TJ	28.05.21	NIL	01.06.21	2 D	Nil
709	43779	LATHA	46	M	TJ	30.05.21	SHTN/T2DM	02.06.21	8 D	2
710	43817	RAJENDRAN	60	M	TJ	30.05.21	HYPERLIPIDEMIA	01.06.21	12 D	1
711	43256	MAHBOOB BEEVI	60	F	TJ	29.05.21	T2DM/SHTN	01.06.21	4 D	2
712	41190	RENUKA	30	F	TJ	23.05.21	NIL	02.06.21	5 D	Nil
713	39099	RAJAN	58	M	TJ	17.05.21	T2DM/SHTN/CKD-50N HD	21.05.21	3 D	3
714	43423	JEYAMANI	80	M	TJ	29.05.21	SHTN	03.06.21	3 D	1
715	41677	BHARATHAN	45	M	TJ	24.05.21	SHTN	02.06.21	6 D	1
716	43696	UTHRAPATHY	64	M	TJ	30.05.21	T2DM	02.06.21	3 D	1
717	41141	PALANIYANDI	62	M	TJ	23.05.21	T2DM	02.06.21	1 D	1
718	16932	RIKSHITHA	16	F	TJ	07.05.21	NIL	02.06.21	1 D	Nil
719	43229	VEERAIYAN	54	M	TJ	28.05.21	LIVER CIRRHOSIS WITH PORTAL HYPERTENSION	03.06.21	5 D	1
720	42467	AGASTIN MARY	82	F	TJ	26.05.21	SHTN	02.06.21	2 D	1
721	40901	JOHARA BEEVI	67	F	TJ	01.06.21	SHTN/CVA	02.06.21	3 D	2
722	44200	DHANAM	80	F	TJ	31.05.21	T2DM/SHTN	02.06.21	3 D	2
723	44255	PANDIYAN	51	M	TJ	01.06.21	NIL	02.06.21	4 D	Nil
724	41351	FATHIMA MARY	72	F	TJ	23.05.21	T2DM/CKD	04.06.21	5 D	2
725	44819	KALAIYAMOORTHY	84	M	TJ	02.06.21	SHTN	03.06.21	7 D	1
726	43626	MATHAVI	47	F	TJ	30.05.21	T2DM	03.06.21	3 D	1
727	42650	MEENA	52	F	TJ	27.05.21	HYPOTHYROIDISM	03.05.21	5 D	1
728	45151	RAMAMOORTHY	56	M	TJ	03.06.21	T2DM/SEIZURE DISORDER/CKD	03.06.21	4 D	3
729	43743	REVATHY	29	F	TVR	30.05.21	NIL	03.06.21	2 D	Nil
730	44856	SARAVANAN	39	M	TJ	03.06.21	T2DM/SHTN	03.06.21	3 D	2
731	41672	SAVITHRI	60	F	TJ	24.05.21	SHTN	03.06.21	2 D	1
732	44459	SREE DEVI	40	F	TJ	01.06.21	T2DM	04.06.21	3 D	1
733	41837	SRIRANGAM	62	F	TJ	25.05.21	NIL	03.06.21	1 D	Nil
734	43720	ALAMELU	51	F	TJ	30.05.21	NIL	03.05.21	2 D	Nil
735	44778	CHANDRAMOHAN	62	M	TJ	02.06.21	T2DM	03.06.21	3 D	1
736	44643	CHOCKALINGAM	57	M	TJ	02.06.21	T2DM	03.06.21	5 D	1
737	44562	GANDHI	46	M	TJ	01.06.21	T2DM	04.06.21	2 D	1
738	43262	KRISHNAN	63	M	TJ	29.05.21	T2DM	03.06.21	2 D	1
739	42818	NATARAJAN	70	M	TJ	27.05.21	NIL	03.06.21	7 D	Nil
740	44836	RATHINAKUMAR	65	M	TJ	03.06.21	T2DM/CAD/SHTN	03.06.21	2 D	3
741	38088	RUKSHANA BEEVI	75	F	TJ	14.05.21	T2DM	03.06.21	4 D	1
742	44802	SAMIKANNU	51	M	TJ	02.06.21	T2DM/CAD	03.06.21	6 D	2
743	45106	SETHURAMAN	65	M	TJ	03.06.21	T2DM/SHTN	04.06.21	5 D	2
744	45217	UMA	40	F	TJ	04.06.21	SLE ON MEDICATION	04.06.21	4 D	1

745	43976	RAMALINGAM	65	M	MDU	31.05.21	CKD	04.06.21	8 D	1
746	45017	RADHAMANI	44	F	TJ	03.06.21	T2DM	04.06.21	2 D	1
747	44799	KALYANASUNDARAM	51	M	TVR	02.06.21	NIL	04.06.21	3 D	NII
748	43455	ANNAL NAVAMANI	69	F	TJ	29.05.21	T2DM/SHTN / B/L TIBIAL OCCLUSION/ ACUTE LIMB ISCHEMIA	05.06.21	6 D	4
749	42483	AMUTHAVALLI	60	F	TJ	26.05.21	T2DM/SHTN	04.06.21	2 D	2
750	42067	ALAMELU	71	F	TJ	25.05.21	NIL	05.06.21	3 D	NII
751	42800	TAMILARASAN	65	M	TJ	25.05.21	NIL	04.06.21	5 D	NII
752	43632	THOMAS EDWIN	50	M	TJ	30.05.21	NIL	04.06.21	4 D	NII
753	44730	KADHIJAMMAL	66	F	TJ	02.06.21	T2DM/SHTN/RHEUMATOID ARTHRITIS/RT FILARIAL LIMB	04.06.21	2 D	4
754	40529	JOHNPETER	60	M	TJ	21.05.21	SHTN/T2DM/COPD	05.06.21	5 D	3
755	45177	ABDUL KAREEM	53	M	TJ	04.06.21	NIL	04.06.21	5 D	NII
756	45046	RAVI	50	M	TJ	03.06.21	T2DM	04.06.21	3 D	1
757	45125	KANNAN	50	M	TJ	04.06.21	CKD	04.06.21	3 D	1
758	43866	APOORVAM	60	F	TJ	30.05.21	T2DM/SHTN	05.06.21	4 D	2
759	43937	SAHUL HAMEED	48	M	TJ	31.05.21	SHTN	06.06.21	18 D	1
760	42157	SHAMUGAVEL	66	M	TJ	25.05.21	T2DM	05.06.21	7 D	1
761	45319	BALASUBRAMANIAN	62	M	TJ	04.06.21	T2DM/SHTN/ SEVERE HEAD INJURY- RIGHT FRONTO-PARIETO- TEMPORAL SUBDURAL HEMORRHAGE	06.06.21	5 D	3
762	44505	ESWARI PANDIYAN	52	F	TJ	01.06.21	T2DM/SHTN/HYPOTHYROIDISM	05.06.21	5 D	3
763	39391	JUNAITHA BEGUM	70	F	TJ	18.05.21	T2DM/SHTN/HYPOTHYROIDISM	05.06.21	3 D	3
764	41465	NEELAVATHI	66	F	TJ	31.05.21	T2DM/SHTN/CAD/ACUTE ON CKD	05.06.21	2 D	4
765	44109	PARAMESHWARI	55	F	TJ	31.05.21	T2DM	05.06.21	8 D	1
766	43453	VISHWANATHAN	82	M	TJ	29.05.21	T2DM/CVA	05.06.21	6 D	2
767	40916	MOHAMMAD FAROOQ	59	M	TJ	22.05.21	SHTN/CAD	05.06.21	4 D	2
768	43020	MURUGAIYAN	77	M	TJ	29.05.21	CAD	05.06.21	3 D	1
769	45050	THAMARASELVI	53	F	TJ	03.06.21	T2DM	05.06.21	4 D	1
770	44074	GOVIDAMMAL	75	F	TJ	31.05.21	CKD	05.06.21	2 D	1
771	43485	ARUMUGAM	65	M	TVR	29.05.21	COPD / COR PULMONALE	06.06.21	3 D	2
772	45170	BALASUBRAMANIAN	71	M	TJ	04.06.21	T2DM/CVA	06.06.21	13 D	2
773	45957	ILAMARAN	35	M	TVR	06.06.21	ARNOLD CHIARI MALFORMATION (OPERATED)	06.06.21	2 D	1
774	44230	KALIYAPERUMAL	75	M	TJ	31.05.21	T2DM	06.06.21	6 D	1
775	44455	KAMALANATHAN	48	M	TJ	01.06.21	NIL	07.06.21	6 D	NII

776	44951	KRISHNAN	78	M	TJ	03.06.21	T2DM/CAD	06.06.21	3 D	2
777	45829	NOOR MUHAMED	78	M	TJ	06.06.21	NIL	06.06.21	2 D	Nil
778	45196	PANCHAVARNAM	70	F	TJ	04.06.21	T2DM/SHTN	07.06.21	2 D	2
779	45057	RAMEEJA BEGAM	65	F	TJ	03.06.21	NIL	07.06.21	6 D	Nil
780	45694	SAGAYASELVI	52	F	TVR	05.06.21	T2DM	07.06.21	5 D	1
781	44406	SARASWATHI	55	F	TJ	01.06.21	CAD	06.06.21	01 D	1
782	42014	SEBASTIAN	66	M	TJ	25.05.21	T2DM/SHTN	07.06.21	2 D	2
783	45362	SENBAGALAKSHMI	31	F	TJ	04.06.21	NIL	07.06.21	2 D	Nil
784	45669	SEVU PANDARINATHAN	80	M	TJ	05.06.21	NIL	06.06.21	2 D	Nil
785	43524	SITHARAMAN	79	M	TJ	29.05.21	BICYTOPENIA FOR EVALUATION	07.06.21	2 D	1
786	42493	THANGARASU	60	M	TJ	26.05.21	T2DM	07.06.21	3 D	1
787	45895	VARATHARAJ	56	M	TJ	06.06.21	T2DM	07.06.21	6 D	1
788	45236	VIDHYA DHARANI	27	F	TJ	04.06.21	T2DM	06.06.21	4 D	1
789	45885	MANI	63	M	TVR	06.06.21	T2DM	08.06.21	2D	1
790	45258	RAMAKRISHNAN	72	M	TJ	04.06.21	T2DM	07.06.21	2D	1
791	23259	ABDUL RAZACK	68	M	TJ	29.05.21	SHTN/OLD PTB	08.06.21	5D	2
792	40892	PALANIVEL	73	M	TJ	26.05.21	CAD	07.06.21	2 D	1
793	41691	MARIADOSS	69	M	TJ	24.05.21	T2DM/CAD	07.06.21	4 D	2
794	44696	AISWARYA	30	F	TJ	02.06.21	SHTN/T2DM/HYPOTHYROID/UNSTABLE ANGINA.	07.06.21	4 D	4
795	45670	SABIYA KANI	52	F	TJ	05.06.21	SHTN	07.06.21	1 D	1
796	45123	BALACHANDRAN	73	M	TJ	07.06.21	SHTN	08.06.21	5 D	1